

**CULTURES CROSS
MINDS MEET**

Program at a Glance

November 14 – 18, 2010

**Ernest N. Morial Convention Center
New Orleans, Louisiana, USA**

Register as a Group and
Save Hundreds of Dollars!

See page 4 for details

Amgen
AstraZeneca
Catalent Pharma Solutions
DPT
Eli Lilly & Co.
Pfizer
Sanofi-aventis

Employees Receive
a \$125 Discount on
Full Registration

See page 4 for details.



aaps[®]
American Association of
Pharmaceutical Scientists



Intertek

Service at a higher level

Intertek's global network of pharmaceutical laboratories provides a diverse range of GLP and cGMP services to support customers engaged in the research, development and manufacture of pharmaceuticals, biopharmaceuticals and related healthcare products.

GLP Bioanalytical Services

- LC-MS/MS
 - Ocular tissue bioanalysis
 - Rapid discovery phase bioanalysis
- Immunochemistry
 - Quantitative immunoassays & immunogenicity assessments
 - Cell-based neutralization assays
- Sample management & handling
- Bioanalytical PK/TK support services

cGMP Analytical Services

- Analytical research & development
 - Stability and dissolution
- Trace metals analysis
- Advanced characterization – pharmaceuticals & biopharmaceuticals

For more information visit

www.intertek.com/pharmaceutical or contact our laboratories listed below.



Experience, innovation,
proven results

Pharmaceutical Services



**Intertek Alta
Bioanalytical LCMS**
El Dorado Hills, CA
Tel. (916) 933-1640

**Intertek Alta
Immunochemistry**
San Diego, CA
Tel. (858) 558-2599

Intertek QTI
Whitehouse, NJ
Tel. (908) 534-4445

Intertek ASG
Manchester, UK
Tel. +44 (161) 721-5247

Intertek BioClin
Athlone, Ireland
Tel. +353 (90) 648-0400

FIP Pharmaceutical Sciences World Congress 2010 in association with AAPS Annual Meeting & Exposition

will feature Keynote speaker

Dr. Tadataka "Tachi" Yamada

Dr. Tadataka "Tachi" Yamada is President of the Bill & Melinda Gates Foundation Global Health Program. In this capacity he oversees grants totalling over \$7 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health. He was formerly Chairman, Research and Development and a Member of the Board of Directors of GlaxoSmithKline.



Dr. Yamada was born in Japan, and completed his education in the United States. He graduated from Stanford University with a Bachelors in history and obtained his M.D. from New York University School of Medicine. After completing his internal medicine training at the Medical College of Virginia he became an investigator in the United States Army Medical Research Institute of Infectious Diseases, trained in gastroenterology at the UCLA School of Medicine and assumed his first faculty position there. He later moved to the University of Michigan where he ultimately became Chairman, Department of Internal Medicine and Physician-in-Chief of the University of Michigan Medical Center before joining GlaxoSmithKline.

A scientist and scholar in gastroenterology, Dr. Yamada is the author of more than 150 original manuscripts on the subject and is the editor of *The Textbook of Gastroenterology*. The studies undertaken by Dr. Yamada and his collaborators led to basic discoveries in the post-translational processing and biological activation of peptide hormones, the structure and function of receptors for hormones regulating gastric acid

secretion, and the regulation of genes involved in the acid secretory process.

In recognition of his contributions to medicine and science he has been elected to membership in the Institute of Medicine of the National Academy of Sciences (US), the Academy

of Medical Sciences (UK) and the National Academy of Medicine (Mexico) and he has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE). He has also been the recipient of numerous awards including the Distinguished Achievement Award in Gastrointestinal Physiology from the American Physiological Society, the Friedenwald Medal from the American Gastroenterological Association, the Distinguished Faculty Achievement Award from the University of Michigan and the Distinguished Medical Scientist Award from the Medical College of Virginia. Dr. Yamada is a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of Physicians, a Past-President of the Association of American Physicians and a Past-President of the American Gastroenterological Association. He has also been a Member of the Board of Directors of the American Board of Internal Medicine and the National Board of Medical Examiners.



Advance your knowledge and exposure at the premier pharmaceutical event. You can also register with your colleagues and SAVE hundreds of dollars by taking advantage of the group discounted rates.

With over 100 programming sessions, this can be your best opportunity to meet colleagues, learn about and promote breakthrough research and technologies, and improve your professional edge.

Registration Special Packages

Group Registration

Take advantage of this opportunity to register you and your colleagues for this meeting and save hundreds of dollars!

Group registration will be applied as follows:

Four fully paid registrations qualify for a \$100.00 discount for everyone in the group.

This policy is NOT applicable for the following registration types:

- Students
- Exhibitors
- Reduced Combination Registration
- One-day and Two-day Registrations
- Expo Hall/Career Center Only

Registration must be in groups of four or more paid registrants from the same organization, and cannot be combined with any other offer. All members of the group must be registered at the same time. Previously registered attendees may not be added to a new group. **Group Registrations are not valid after October 8, 2010 and are available through online registration only.**

To register your group online, go to the registration site

<http://www.pswc2010.org>

Save up to 10 Percent!

Reduced Combination Registration Fee

Register for the following and become eligible for a reduced combination registration fee:

- A FIP PSWC 2010/AAPS Annual Meeting & Exposition Short Course and
- FIP PSWC 2010/AAPS Annual Meeting & Exposition

Choose the appropriate fee on the PSWC Meeting registration website and save up to 10%.

NOTE: Discounts not available for students or one-day registrants and cannot be combined with group registration. Discounts are not available after October 8, 2010.



\$125 Discounted Registration Available to the Following Companies:



Register online and use the Sustaining Sponsor registration. Contact registration@aaps.org for the company discount code. Receive \$125 off your registration for the FIP PSWC 2010/AAPS Annual Meeting & Exposition. **The deadline for the discount is October 8, 2010.** The discount is not available for combination registrations, one-day or exposition only registration. Discount is applicable only for the FIP PSWC 2010/AAPS Annual Meeting & Exposition Group registrations, and not to workshop, short course or open forum registrations.



See you in New Orleans!

The most celebrated and historic core of this Louisiana city — including the Faubourg Marigny, French Quarter, Central Business District, Warehouse and Arts District, Magazine Street, Garden District, Audubon Park and Zoo and St. Charles Avenue — remains both physically and spiritually intact and is thriving. The cultural riches, sensual indulgences and unparalleled service that define the New Orleans experience continue to flourish, as they have for centuries. The city is open, as historically and culturally rich and charming as ever, and eager to welcome visitors again. With more than 28,000 hotel rooms, famed restaurants, and vibrant music clubs, New Orleans attracts and accommodates more than 10 million people each year.

For more information on all New Orleans has to offer you, visit www.neworleanscvb.com/pswc2010.

The FIP PSWC 2010/AAPS Annual Meeting & Exposition will be held at the Ernest N. Morial Convention Center New Orleans (MCCNO), conveniently located to major points throughout the city.

The MCCNO lays just steps away from the world-famous attractions of the French Quarter, while the historic St. Charles streetcar line runs past the elegant homes of the Garden District. The excitement of New Orleans transforms an obligatory business trip into an unexpected experience. The MCCNO is approximately 15 miles from Louis Armstrong New Orleans International Airport.

For more information on the Ernest N. Morial Convention Center New Orleans, visit www.mccno.com.

Ernest N. Morial Convention Center New Orleans
900 Convention Center Blvd.
New Orleans, LA 70130

Co-Sponsoring & Supporting Organizations

CO-SPONSORS:



SUPPORTED BY:



Visit the SOTAX
Booth #1325 at
AAPS New Orleans



Zymark

Fully Automated Solutions for Dissolution, Content Uniformity and Assay Testing

- ▶ UV and HPLC/UPLC Coupling
- ▶ Empower Communication
- ▶ Semi Automated Solutions
- ▶ Client/Server Software Solutions
- ▶ Services and validations
- ▶ Method Development and Transfer Expertise

www.sotax.com | sotaxusa@sotax.com



Saturday, November 13, 2010

7:00 am – 5:00 pm

Registration

8:30 am – 5:00 pm

AAPS Executive Council Meeting

2:00 pm – 5:00 pm

Speaker Ready Room

PSWC 2010 CONGRESS FOR STUDENTS AND POSTDOCTORAL FELLOWS

An additional fee is required to attend this meeting.

8:00 am – 10:00 am

Plenary Session

Drug Discovery for Neglected Diseases:

The Essential Ps

William Charman, Ph.D.

Monash University

The Pharmaceutical Sciences in 2020:

Four Scenarios

Daan Crommelin, Ph.D.

Utrecht University

**Critical Research Techniques for
Pharmaceutical R&D**

Mario Rocci, Jr., Ph.D.

Icon Development Solutions

10:30 am – 12:00 pm

Poster Session

1:00 pm – 2:00 pm

Breakout Sessions

How to Advance your Career in Academia

Speaker to be Determined

How to Advance your Career in Industry

Speaker to be Determined

**How to Advance your Career in Government
Agencies**

Speaker to be Determined

2:00 pm – 3:00 pm

Breakout Sessions

Women in Pharmaceutical Sciences

Speaker to be Determined

Resumé Writing

Speaker to be Determined

Job Interview Techniques

Speaker to be Determined

3:30 pm – 5:00 pm

Poster Session

5:00 pm – 6:00 pm

Reception

PRE-CONGRESS WORKSHOPS

An additional fee is required to attend pre-conference workshops.

8:30 am – 5:00 pm

**AAPS Workshop on Contemporary Challenges and
Advances Impacting the Development of Veterinary
Pharmaceuticals**

(Day One of Two-Day Workshop)

8:30 am – 5:00 pm

**AAPS Workshop on Harmonization of Regulatory
Approaches for Evaluating Therapeutic Equivalence
and Interchangeability of Multisource and Complex
Drug Products**

(Day One of Two-Day Workshop)

8:30 am – 5:00 pm

**USP Workshop on the Pharmacopeia's Role in
Improving Global Health**



Co-sponsored by AAPS

(Day One of Two-Day Workshop)

8:30 am – 5:00 pm

**ACCP Workshop on 6th International Symposium
on Microdialysis in Drug Research and
Development 2010**



Co-sponsored by AAPS

(Day One of Two-Day Workshop)

8:30 am – 5:00 pm

**CRS Workshop on Using Population
Pharmacokinetics to Support the Development
of Clinically Relevant Specifications for Extended
Release Formulations**



Co-sponsored by AAPS

(One-Day Workshop)

Sunday, November 14, 2010

7:00 am – 7:00 pm

Registration

7:00 am – 5:00 pm

Speaker Ready Room

8:00 am – 5:00 pm

Press Room

12:00 pm – 5:00 pm

Student Lounge

12:00 pm – 5:00 pm

International Lounge

PSWC 2010 CONGRESS FOR STUDENTS AND POSTDOCTORAL FELLOWS

An additional fee is required to attend this meeting.

7:45 am – 9:45 am

Graduate Student Symposium in Biotechnology (BIOTEC)

Sponsored by



Graduate Student Symposium in Drug Design & Development (DDD)

Graduate Student Symposium in Formulation Design & Development (FDD), Manufacturing Science & Engineering (MSE) and Physical Pharmacy & Biopharmaceutics (PPB)

Sponsored by



Bristol-Myers Squibb Company

10:00 am – 12:00 pm

Graduate Student Symposium in Analysis & Pharmaceutical Quality (APQ)

Sponsored by



APQ
AAPS ANALYSIS AND
PHARMACEUTICAL QUALITY
SECTION

Graduate Student Symposium in Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM) and Clinical Pharmacology & Translational Research (CPTR)

Sponsored by



Answers That Matter.

12:00 pm – 1:00 pm

Mentoring Luncheon

1:00 pm – 2:30 pm

Poster Session

PRE-CONGRESS WORKSHOPS

An additional fee is required to attend pre-conference workshops.

8:30 am – 4:00 pm

AAPS Workshop on Contemporary Challenges and Advances Impacting the Development of Veterinary Pharmaceuticals

(Day Two of Two-Day Workshop)

8:30 am – 4:00 pm

AAPS Workshop on Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource and Complex Drug Products

(Day Two of Two-Day Workshop)

8:30 am – 4:00 pm

USP Workshop on the Pharmacopeia's Role in Improving Global Health



U.S. PHARMACOPEIA
The Standard of QualitySM

Co-sponsored by AAPS

(Day Two of Two-Day Workshop)

8:30 am – 4:00 pm

ACCP Workshop on 6th International Symposium on Microdialysis in Drug Research and Development 2010



Co-sponsored by AAPS

(Day Two of Two-Day Workshop)

Monday, November 15 • Program-at-a-Glance

SHORT COURSES

An additional fee is required to attend short courses.

8:30 am – 4:00 pm

Short Course #1

Stability Testing in Pharmaceutical Development
(APQ, MSE & FDD)

Short Course #2

Mechanistic PK/PD Modeling
(PPDM, CPTR, PCOL)

Short Course #3

**ICH Guidelines Q8, Q9, Q10 and Q11:
How Do They all Fit Together?**
(APQ & RS)

Short Course #4

**Nanotechnology from A-Z: Achievement in
Drug Delivery and Tissue Engineering**
(FDD & PPB)

Short Course #5

**Helping the Medicine Go Down - Pediatric
Medicines: Formulation, Manufacturing and
Compliance Challenges**
(FDD, MSE & RS)

Short Course #6

**Developments in Technologies for Process
Related Impurities Detection and Identification
for Biologics**
(BIOTEC, RS & APQ)

12:00 pm – 1:00 pm

Short Course/Workshop Lunch

4:30 pm – 6:30 pm

Opening Session

Keynote Address

Tadataka “Tachi” Yamada, M.D.
President
*Bill & Melinda Gates Foundation
Global Health Program*

FIP Presidential Address

AAPS Presidential Address

Awards Presentations

Welcome Reception

Immediately Following the Opening Session
Hilton Riverside Hotel

Monday, November 15, 2010

7:00 am – 6:00 pm

Registration

7:00 am – 5:00 pm

Speaker Ready Room

7:00 am – 5:00 pm

Press Room

7:00 am – 5:00 pm

Student Lounge

7:00 am – 5:00 pm

International Lounge

SESSION TOPIC KEY

(APQ) Analysis and Pharmaceutical Quality
(BIOTEC) Biotechnology
(CPTR) Clinical Pharmacology and Translational Research
(DDD) Drug Design and Discovery
(FDD) Formulation Design and Development
(MSE) Manufacturing Science and Engineering
(PPB) Physical Pharmacy and Biopharmaceutics
(PPDM) Pharmacokinetics, Pharmacodynamics and Drug Metabolism
(RS) Regulatory Sciences

(E&C) Education and Curriculum
(ES) Environmental Sciences
(GH) Global Health
(MCNP) Medicinal Chemistry and Natural Products
(PCOL) Pharmacology and Biochemistry
(SS) Safety Sciences

Please visit the full Preliminary Program at www.pswc2010.org for a listing of sessions by topic track.

MONDAY MORNING ROUNDTABLES

8:00 am – 10:00 am

**Development of Effective Fixed Dose
Combination Therapies for Global Diseases:
Recent Successes and Advances**
(PPB & GH)

Session Chairs

Tycho H. Heimbach, Ph.D.
Novartis Pharmaceuticals

Handan He, Ph.D.
Novartis Pharmaceuticals

MONDAY MORNING ROUNDTABLES

8:00 am – 10:00 am (continued from page 9)

Saving Lives with Combined Antimalarial Therapies via Optimizing Dosing Regimen and PK/PD in Children and Pregnant Women. (Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, Coartem)

Jan-Stefan VanderWalt, Ph.D.
University of Cape Town

Finally Beating Malaria: Successful Development of a Fixed Dose Combination of Artemether and Lumefantrine

Unmesh Deodhar, Ph.D.
Novartis Pharma AG

Impacting HIV Patients' Lives Around the Globe: Successful Development Fixed Dose Combination of Three Drugs: Efavirenz, Tenofovir and Emtriva

Munir Hussain, Ph.D.
Bristol-Myers Squibb

Pharmacogenetics: A Testing Issue (CPTR & PPDM)

Session Chairs

Lawrence L. Fleckenstein, Ph.D.
University of Iowa

David A. Flockhart, M.D., Ph.D.
Indiana University

Clinically Available Pharmacogenomic Tests

David A. Flockhart, M.D., Ph.D.
Indiana University

Challenges of the Clinical Application of Pharmacogenetic Testing

Kathryn A. Phillips, Ph.D.
University of California, San Francisco

FDA Perspective on Pharmacogenetic Testing

Lawrence J. Lesko, Ph.D. (Invited)
U.S. Food and Drug Administration

Can Nanoparticles be Simultaneously Used for Multimodality Imaging and Targeted Drug Delivery? (PPB & FDD)

Session Chairs

Duxin Sun, Ph.D.
University of Michigan

Gert Storm, Ph.D.
Utrecht University

Delivery of siRNA and Peptide for Cancer Therapy

Leaf Huang, Ph.D.
University of North Carolina

MRI Detection of Imaging-guided Drug Delivery: The Role of Lipo-cest Agents

Silvio Aime, Ph.D.
University of Torino

Mimicking the Design of Nature's Own Nanoparticles to Create Multifunctional Agents

Willem Mulder, Ph.D.
Mount Sinai School of Medicine

Analytical Instrument Qualification: Towards Globalization (APQ)

Session Chairs

Paul Smith, Ph.D.
Perkin-Elmer

Frank Gargiulo, M.S.
MannKind Corporation

Somak Das, M.S.
Bristol-Myers Squibb

AIQ: A USP Perspective

Horacio Pappa, Ph.D.
U.S. Pharmacopeia

AIQ in QA/QC Operations

Nicholas Buhey, Ph.D.
U.S. Food and Drug Administration

A European Perspective on AIQ

Bob McDowell, Ph.D.
Scientific Consultant

Sharing Global Best Practices in Educating Pharmaceutical Scientists (MSE & E&C)

Session Chairs

Jian-Xin Li, Ph.D.
Evonik Degussa Corporation

Daan J. Crommelin, Ph.D.
Top Institute Pharma

Asian Perspective: Education and Training Programs

Paul Wan Sia Heng, Ph.D.
National University of Singapore

European Perspective: Public Private Partnerships and their Role in Education

Daan J. Crommelin, Ph.D.
Top Institute Pharma

U.S. Perspective: Industrial Pharmacy Education for the Future

Larry Augsburg, Ph.D.
University of Maryland

Monday, November 15 • Program-at-a-Glance

Customized Vaccines for the Future (BIOTEC)

Session Chairs

Camilla Foged, Ph.D.

The Danish University of Pharmaceutical Sciences

Enrico Mastrobattista, Ph.D.

Utrecht Institute for Pharmaceutical Sciences

Customized Vaccines for the Future

Derek O'Hagan, Ph.D.

Novartis Vaccines & Diagnostics

Customized Vaccines for the Future: Needles or Needleless?

Wim Jiskoot, Ph.D.

Leiden University

Vaccines for the 21st Century

Christian Mandl, Ph.D., M.D.

Novartis Vaccines & Diagnostics

MONDAY MORNING PROFESSIONAL DEVELOPMENT SESSION

8:00 am – 10:00 am

Alternative Careers: The Path Less Traveled

Clifford Minz, Ph.D.

BioCrowd.com

PLENARY SESSION

10:00 am – 12:00 pm

Presentation Title to be Determined

Leslie Z. Benet, Ph.D.

University of California, San Francisco

Presentation Title to be Determined

Michael Karas

Goethe Universitat

Third Speaker to be Determined

AWARDS CEREMONY


12:00 pm - 1:00pm

EXPOSITION AND CAREER CENTER

12:00 pm – 5:30 pm

Exposition

AAPS Career Center

Funded by a Grant from  AstraZeneca
life inspiring ideas

CONTRIBUTED PAPERS POSTER SESSION

1:00 pm – 5:00 pm

HOT TOPICS

12:15 pm – 1:30 pm

Topic #1 to be Determined

Topic #2 to be Determined

AAPS FOCUS GROUP MEMBERSHIP

MEETINGS

12:15 pm – 1:15 pm

MONDAY AFTERNOON PROFESSIONAL DEVELOPMENT SESSIONS

1:00 pm – 3:00 pm

Making the Most out of the Conference

Brianna Blaser, Ph.D.

AAAS/Science Careers

2:00 pm – 4:00 pm

How to Survive a Merger

Megan Driscoll

PharmaLogics

MONDAY AFTERNOON SYMPOSIA

Monday afternoon symposia are supported by a grant from

 sanofi aventis

Because health matters

1:30 pm – 4:00 pm

Pharmaceuticals Without Borders I: Developing and Delivering Medicines to Underserved Populations (GH)

Session Chairs

Lawrence L. Fleckenstein, Ph.D.

University of Iowa

William Charman, Ph.D.

Monash University

Vaccinology and Global Health: New Technologies Create Global Opportunities

Andrin Oswald, M.D.

Novartis Vaccines & Diagnostics

The Bill & Melinda Gates Foundation's Strategy on Neglected Tropical Diseases

Julie Jacobson, M.D.

Bill and Melinda Gates Foundation

MONDAY AFTERNOON SYMPOSIA

Monday afternoon symposia are supported by a grant from

sanofi aventis

Because health matters

1:30 pm – 4:00 pm (continued from page 11)

Contribution of Public and Private Partnerships to Delivering Low-cost Pharmaceuticals

Simon Croft, Ph.D.

London School of Hygiene and Tropical Medicine

Nature's Chemical Diversity: Science and Practice (DDD & MCNP)

Session Chairs

Maureen A. McKenzie, Ph.D.

Denali BioTechnologies, Inc.

De-an Guo, Ph.D.

Shanghai Research Center

Targeted Phytochemicals from Selected Plants and their Biotechnology

Peter Kaufman, Ph.D.

University of Michigan

Marine Drug Discovery: Novel Leads from Cyanobacteria and their Modes of Action

Hendrik Luesch, Ph.D.

University of Florida

Drug Discovery and Early-phase Development of Anti-Alzheimers Agents from Natural Products

John R. Cashman, Ph.D.

Human BioMolecular Research Institute

Microarray Analysis as a Tool to Elucidate the Mechanism of Action of St. John's Wort

Veronika Butterweck, Ph.D.

University of Florida

Modern Research of Chinese Herbal Medicines

De-an Guo, Ph.D.

Shanghai Research Center

Nutraceuticals: Quality by Design (MSE & FDD)

Session Chair

Walter Chambliss, Ph.D.

University of Mississippi

Critical Quality Attributes for Dietary Supplements

Brad Williams (Invited)

U.S. Food and Drug Administration

Managing Quality of Botanical Dietary Supplements through Implementation of cGMP Concepts: Challenges and Opportunities

Ikhan Khan, Ph.D.

University of Mississippi

Experiences Implementing Quality Systems in a Botanical Supplement Manufacturing Operation in the U.S.

Loren Israelsen

United Natural Products Alliance

Lessons Learned from Implementing Quality Systems in China

De-An Guo, Ph.D.

Chinese Academy of Sciences

Drug-drug Interactions: Are they Predictable? (PPDM)

Session Chairs

R. Scott Obach, Ph.D.

Pfizer Inc.

Akihiro Hisaka, Ph.D.

University of Tokyo

Title to be Determined

Akihiro Hisada, Ph.D.

University of Tokyo

Title to be Determined

Karen Yeo, Ph.D.

SimCYP Ltd.

Title to be Determined

Kazuya Maeda, Ph.D.

University of Tokyo

Title to be Determined

Ping Zhao, Ph.D. (Invited)

U.S. Food and Drug Administration

Bioanalytical Procedures and Regulation: Towards Global Harmonization (APQ & RS)

Session Chairs

Mark E. Arnold, Ph.D.

Bristol-Myers Squibb

Brian P. Booth, Ph.D.

U.S. Food and Drug Administration

Howard M. Hill, Ph.D.

Huntingdon Life Sciences

Introduction

Brian P. Booth, Ph.D. (Invited)

U.S. Food and Drug Administration

Presentation Title to be Determined

Howard M. Hill, Ph.D.

Huntingdon Life Sciences

Regulated Bioanalysis in Support of Global Drug Registration Applications: An Industry Perspective

Eric J. Woolf, Ph.D.

Merck and Co., Inc.

An EU Regulatory Perspective on Bioanalytical Harmonization

Olivier LeBlaye, Pharm.D.
AFSSAPS (French Health Products Safety Agency)

Treating Blindness in the Developing World (GH & FDD)

Session Chairs

Adrian Raiche, Ph.D.
SurModics Pharmaceuticals

Ruiwen Shi, Ph.D.
Allergan

Prevalence of Preventable and Treatable Blindness: A Global Health Perspective

Peter Ackland
International Agency for Prevention of Blindness

Case Study: Global Distribution of Avastin for Ocular Application

Malik Kahook, M.D.
University of Colorado Denver

Strategies for Ophthalmic Formulation Development

Michelle Marra, Ph.D.
Pfizer Global Research & Development

Developing Thermostable Vaccines: Progress, Challenges and Opportunities

Dexiang Chen, Ph.D.
PATH

Improved Pulmonary Delivery of Drugs and Biologics (FDD & PPB)

Session Chairs

Amit Misra, Ph.D.
Central Drug Research Institute

Hirokazu Okamoto, Ph.D.
Meijo University

Peter York, Ph.D., D.Sc.
Institute of Pharmaceutical Innovation

Pulmonary Delivery of Microspheres that Activate Lung Macrophages Infected with Tuberculosis Bacteria

Amit Misra, Ph.D.
Central Drug Research Institute

Particle Engineering for Respiratory Drug Delivery

Peter York, Ph.D., D.Sc.
Institute of Pharmaceutical Innovation

Pulmonary Treatment of Tuberculosis: Isn't the Dose Too Large for Us?

Henderik W. Frijlink, Ph.D.
University of Groningen

Progress in Modeling Disease Progression (PPDM & CPTR)

Session Chairs

Liping Zhang, Ph.D.
Bristol-Myers Squibb

Nick Holford, M.D., M.S.
University of Auckland

Peter Milligan, Ph.D.
Pfizer Inc.

Disease Systems Analysis: Utility of Collaborative Data Resources

Meindert Danhof, Ph.D.
Leiden University

Disease Modifying Treatments: Design and Analysis for Demonstrating Disease Modifying Effects

Nick Holford, M.D., M.S.
University of Auckland

Modeling of the Tumor Growth: Survival Link During Anti-cancer Treatment

Rene Bruno, Ph.D.
Certara

Linking Short-term Viral Kinetics to Long-term Progression and Outcome

Alan Perelson, Ph.D.
Los Alamos National Laboratory

MONDAY AFTERNOON ROUNDTABLES

Monday afternoon roundtables and mini-symposia are supported by a grant from



2:00 pm – 4:00 pm

Antibody Interference in Bioanalytical Methods (BIOTEC & APQ)

Session Chairs

Joleen T. White, Ph.D.
Bristol-Myers Squibb

Michaela Golob, Ph.D.
MerckSerono

Introduction to Risk-based Approach to Evaluating Potential Interference

Michaela Golob, Ph.D.
MerckSerono

MONDAY AFTERNOON ROUNDTABLES

Monday afternoon roundtables and mini-symposia are supported by a grant from



2:00 pm – 4:00 pm (continued from page 13)

“Houston, We Have a Problem Here”: How to Spot Interference from an Anti-drug Antibody on an Existing PK Immunoassay and What Might be Done to Mitigate the Problem

Jeffrey M. Sailstad
Sailstad and Associates Inc.

Reactive Impurities in Excipients: Characterization and Stabilization Strategies (FDD & PPB)

Session Chairs

Ajit S. Narang, Ph.D.
Bristol-Myers Squibb

Sherif Badawy, Ph.D.
Bristol-Myers Squibb

Case Studies of Drug Product Instability Attributed to Reactive Components of Pharmaceutical Excipients

Robert Reed, Ph.D.
Celsion Corporation

Controlling Reactive Components in Polymeric Pharmaceutical Excipients

Shaukat Ali, Ph.D.
BASF Corporation

Characterization and Control of Reactive Components in PVA-based Film Coatings

Thomas P. Farrell, Ph.D.
Colorcon

Non-clinical Dose Formulation: Time for Regulatory Guidance? (RS & APQ)

Session Chair

Peter D. Bryan, Ph.D.
Celgene Corporation

NCDFA: A Toxicologist Prospective Speaker to be Determined

Investigation of Out-of-Specification Results for NCDFA

Rodrigo Laureano, M.S.
Celgene Corporation

NCDFA: A Regulatory Prospective

Peter D. Bryan, Ph.D.
Celgene Corporation

Solid State Forms of Drugs and Intellectual Property (RS, PPB & FDD)

Session Chairs

Keiji Yamamoto, Ph.D.
Chiba University

Abbie E. Gentry, Ph.D.
McNeil Consumer Healthcare

Crystal Design for the Optimal Performance of Solid Pharmaceuticals

Katsuhide Terada, Ph.D.
Toho University

Strategies for Patenting Novel Crystalline Forms of Drug Products

Jeffrey A. Lindeman, Ph.D.
O'Brien Jones PLLC

Patent Implications of Amorphous States

Eyal H. Barash, J.D.
Aptuit Inc.

MONDAY AFTERNOON MINI-SYMPOSIA

Monday afternoon roundtables and mini-symposia are supported by a grant from



2:00 pm – 4:00 pm

AAPS/ACCP Joint Session: Genomics Issues and Solutions in Oncology, Drug Discovery and Development (CPTR & DDD)

Session Chairs

Daniel E. Salazar, Ph.D.
Daiichi Sankyo Pharma Development

Hyo-Jeong Kuh, Ph.D.
The Catholic University of Korea

Overview of Genomics and Other Biomarkers in Oncology Drug Discovery and Development

Gary Kelloff, M.D.
National Institute of Health Sciences

Oncogenomics as a Basis for Cancer Therapy Development

Axel Ulrich, Ph.D.
Max Planck Institute for Biochemistry

The Oncologists 6th Vital Sign: A Context of Vulnerability

Daniel D. Von Hoff, M.D.
Translational Genomics Research Institute

Transport Proteins I: Regulatory Mechanisms that Modulate Drug Disposition and Response (PPDM & PCOL)

Session Chairs

Guofeng You, Ph.D.
Rutgers University

Kathleen M. Giacomini, Ph.D.
University of California, San Francisco

The Diversity in Post-translational Modification of Drug Transporters: Known and Novel

Guofeng You, Ph.D.
Rutgers University

Gene Regulation of Drug Transporters: Implications to Drug Disposition

Ken-ichi Inui, Ph.D.
Kyoto University Hospital

SNPs in Noncoding Regions of Transporters: Role in Variation in Transporter Expression and Drug Response

Kathleen M. Giacomini, Ph.D.
University of California, San Francisco

AAPS RESEARCH ACHIEVEMENT AWARD LECTURES

4:00 pm – 5:00 pm

Analysis and Pharmaceutical Quality (APQ) Research Achievement Award Lecture

Biopharmaceutics (PPB) Research Achievement Award Lecture

AAPS JOINT MEMBERSHIP MEETINGS AND RECEPTIONS

5:00 pm – 7:30 pm

Analysis & Pharmaceutical Quality (APQ) Section

Biotechnology (BIOTEC) Section

Clinical Pharmacology & Translational Research (CPTR) Section

Drug Design & Discovery (DDD) Section

Formulation Design & Development (FDD) Section

Manufacturing Science & Engineering (MSE) Section

Physical Pharmacy & Biopharmaceutics (PPB) Section

Regulatory Sciences (RS) Section

Tuesday, November 16, 2010

6:00 am – 5:00 pm
Speaker Ready Room

7:00 am – 5:30 pm
Registration

7:00 am – 5:00 pm
Press Room

7:00 am – 5:00 pm
Student Lounge

7:00 am – 5:00 pm
International Lounge

TUESDAY MORNING SUNRISE SESSIONS

7:00 am - 8:15 am

High pH Mobile Phase (LC-MS/MS) to Optimize Analytical Sensitivity (APQ)

Session Chair

Fabio Garofolo, Ph.D.
Algorithme Pharma, Inc.

History and Fundamentals of the Use of High pH Mobile Phase in Bioanalysis: A Review of the Literature

Ray Briggs, Ph.D.
Icon Development Solutions

Application of High pH Mobile Phase in LC-ESI(+)-MS/MS Under Reverse Phase and Hydrophilic Interaction Chromatography Mode to Obtain Optimal Sensitivity for Bioanalysis

Fabio Garofolo, Ph.D.
Algorithme Pharma, Inc.

Nose to Brain Delivery: Reality or Just Blowing Smoke? (FDD & PPDM)

Session Chairs

Dennis O'Connor, Ph.D.
Boehringer-Ingelheim

Lisbeth Illum, M.Pharm, Ph.D., D.Sc.
Critical Pharmaceuticals Limited

Nose to Brain Drug Delivery

Lisbeth Illum, M.Pharm, Ph.D., D.Sc.
Critical Pharmaceuticals Limited

Intranasal Delivery of Drugs to the Brain

Shyeilla Dhuria, Ph.D.
Novartis Pharmaceuticals Corporation

TUESDAY MORNING SUNRISE SESSIONS

7:00 am – 8:15 am (continued from page 15)

Device Characteristics for Nose to Brain Drug Delivery

Per Djupesland, M.D., Ph.D.
OptiNose

Placental ABC Transporters: Impact on Drug/Xenobiotic Disposition and Toxicity (PPDM & CPTR)

Session Chairs

Qingcheng Mao, Ph.D.
University of Washington

Takuya Fujita, Ph.D.
Ritsumeikan University, Faculty of Pharmaceutical Sciences

Role of Placental P-Glycoprotein and BCRP in Fetal Drug Exposure

Qingcheng Mao, Ph.D.
University of Washington

Transport Activity and Impact of Human Placental Multidrug Resistance-associated Proteins (MRPs)

Phillip M. Gerk, Ph.D., Pharm.D.
Virginia Commonwealth University

PEGylated Proteins: Analytical and Pharmacokinetic Issues (BIOTEC & PPDM)

Session Chairs

Murli Krishna, Ph.D.
Bristol-Myers Squibb

Yoshinobu Takakura, Ph.D.
Kyoto University

The Current Status and Challenges of PEGylated Proteins

Francesco M. Veronese, Ph.D.
University of Padua

Experimental Challenges in the Bioanalysis of PEGylated Peptides

Mark J. Rose, Ph.D.
Amgen Inc.

Development of Novel Strategies for PEGylated Proteins

Yasuo Tsutsumi, Ph.D.
Osaka University

The Art and Science of Model Evaluation (PPDM & CPTR)

Session Chairs

Liping Zhang, Ph.D.
Bristol-Myers Squibb

Saeho Chong, Ph.D.
Seoul National University

Basic Concepts for Population Pharmacometric Model Building and Diagnostics

Liping Zhang, Ph.D.
Bristol-Myers Squibb

Methods and Techniques for Population Pharmacometric Model Building and Diagnostics

Andrew Hooker, Ph.D.
Uppsala University

CONTRIBUTED PAPERS POSTER SESSION

8:00 am – 12:00 pm

TUESDAY MORNING PROFESSIONAL DEVELOPMENT SESSIONS

8:00 am – 10:00 am

Work/Life Balance

Brianna Blaser, Ph.D.
AAAS/Science Careers

9:00 am – 11:00 am

Facilitation Skills

Megan Driscoll
PharmaLogics

10:00 am – 12:00 pm

Social Media and Career Development for Life Sciences

Clifford Mintz, Ph.D.
BioCrowd.com

TUESDAY MORNING SYMPOSIA

8:30 am - 11:00 am

ASCPT/AAPS Joint Symposium: Phase 0 Pharmacodynamics Trials in Oncology – A Paradigm Shift in Drug Development? (CPTR & PPDM)

Session Chairs

David Y. Mitchell, Ph.D.
Mitchell Pharmaceutical Consulting

Alex Sparreboom, Ph.D.
St. Jude Children's Research Hospital

Speakers and Presentation Titles to be Determined

Neutralizing Antibodies: Alternatives to Cell-based Assays (BIOTEC & APQ)

Session Chairs

George R. Gunn, Ph.D.
Centocor Research & Development

Deborah Finco, M.S.
Pfizer Inc.

Case Studies: Comparative Analysis of Cell-based and Competitive Ligand Binding Assays for the Characterization

Bonnie Wu, Ph.D.
Centocor Research & Development

Nonclinical Case Study Using Competitive Ligand Binding and Cell-based Assay Formats for Assessing Neutralizing Antibodies

Daniel J. Baltrukonis, M.A.
Pfizer Inc.

Anti-ranibizumab Neutralizing Antibody Assays: A Ligand-Binding Immunoassay with Improved Sensitivity Relative to a Cell-based Assay

Mauricio Maia, Ph.D.
Genentech/Roche

Intelligent Pharmaceutical Product Design and Processing using Data Mining Methods (MSE & FDD)

Session Chairs

Peter York, Ph.D., D.Sc.
Institute of Pharmaceutical Innovation

Elizabeth Colbourne, Ph.D.
Intelligensys Ltd.

Intelligent Design and Manufacturing of Solid Dosage Forms in the 21st Century

Murat Turkoglu, Ph.D.
Marmara University

Neural and Evolutionary Computing in Pharmaceutical Formulation

Elizabeth Colbourne, Ph.D.
Intelligensys Ltd.

A Novel Statistical Approach in Pharmaceutical Formulation Development

Kozo Takayama, Ph.D.
Hoshi University

Applications of Neural Network Data Mining to Drug Delivery Systems

Svetlana Ibric, Ph.D.
Belgrade University

The Gut Wall as a Metabolic Barrier to Drug Development (PPDM & PPB)

Session Chairs

Manthana V. Varma, Ph.D., M.S.
Pfizer Inc.

J. Brian Houston, Ph.D., D.Sc.
University of Manchester

Interplay Between Dissolution, Passive Permeability, Affinity to Efflux Transporters and Gut Wall Metabolism on the Fraction Absorbed and Metabolized During Gut First-pass: How Quantitative Can We Get Beyond BCS Classification and to what Effect?

Amin Rostami-Hodjegan, Ph.D., Pharm.D.
University of Sheffield

Consideration to Physicochemical and Biochemical Aspects in Evaluating the Role of Gut-wall Metabolism to Oral Bioavailability

Manthana V. Varma, Ph.D., M.S.
Pfizer Inc.

In Vitro-In Vivo Extrapolation of High Intestinal First-pass Extraction: How Good are our Predictions?

Aleksandra Galetin, Ph.D.
University of Manchester

Influence of Dietary Substances on the Intestinal First-pass Extraction of Drugs

Mary F. Paine, Ph.D., R.Ph.
University of North Carolina

Translation of Pharmaceutical Science to Practice (CPTR & E&C)

Session Chairs

Toshiyuki Sakaede, Ph.D.
Kyoto University

Cynthia Reilly
American Society of Health-System Pharmacists

Metabolic Analysis of Serum Specimens from Patients Suffering from Drug-induced Liver Injury: Towards Translational Research

Hiroshi Suzuki, Ph.D.
University of Tokyo

Title to Be Determined

Shiew-Mei Huang, Ph.D. (Invited)
U.S. Food and Drug Administration

Biological Effects of Blood Glucose Level Control

Tatsuro Yagami, Ph.D.
Himeji Dokkyo University

TUESDAY MORNING SYMPOSIA

8:30 am – 11:00 am (continued from page 17)

Blockbuster Trials Evaluating Tight Glycemic Control In Critically Ill Patients: Confirming Impact and Implementing Change

Judith Jacobi, Pharm.D., FCCM
Clarian Health

Affinity-based Media: Analytical Aspects and Applications (APQ)

Session Chairs

Jun Haginaka, Ph.D.
Mukogawa Women's University

Irving W. Wainer, Ph.D.
National Institutes of Health

Cellular Membrane Chromatography: Working at the Intersections of Pharmacology and Chromatographic Science

Irving W. Wainer, Ph.D.
National Institutes of Health

Enzyme-based Columns for Chiral Separation and Reactions

Gabriella Massolini, Ph.D.
University of Pavia

Highly Selective Enrichment of Phosphopeptides by Hydroxy Acid-modified Metal Oxide Chromatography for Phosphoproteome Analysis

Yasushi Ishihama, Ph.D.
Keio University

Monodispersed Molecularly Imprinted Polymers for Pharmaceutical and Biomedical Analysis

Jun Haginaka, Ph.D.
Mukogawa Women's University

The Revival of Synthetic Peptides and Small Proteins in Biopharmaceuticals (BIOTEC & DDD)

Session Chair

Tudor Arvinte, Ph.D.
University of Geneva

Title to Be Determined

Gregoire Schwach, Ph.D.
Ferring Pharmaceuticals A/S

Title to Be Determined

Sachin Mittal, Ph.D.
Merck Research Laboratories

Title to Be Determined

Gunther Loidl, Ph.D.
Bachem AG

Title to Be Determined

Tudor Arvinte, Ph.D.
University of Geneva

TUESDAY MORNING ROUNDTABLES

9:00 am - 11:00 am

A Close Look at Subvisible Particles in Protein Therapeutics (BIOTEC & APQ)

Session Chairs

Wim Jiskoot, Ph.D.
Leiden University

John F. Carpenter, Ph.D.
University of Colorado

Applications of Subvisible Particle Analysis in the Development of Protein Therapeutics

Mariana Dimitrova, Ph.D.
MedImmune

Understanding of Subvisible Particles in Protein Therapeutic Products

Jun Liu, Ph.D.
Genentech, Inc.

Visualizing Subvisible Particles in an Academic Setting

Wim Jiskoot, Ph.D.
Leiden University

How Predictive are Animal Models of Clinical Efficacy? (CPTR & PPDM)

Session Chairs

Arnab Mukherjee, Ph.D.
Pfizer Inc.

Jing Liu, Ph.D.
Pfizer Inc.

How to Get it Right More Often: An Industry Perspective

Don Nichols, Ph.D.
Pfizer Global Research & Development

Mechanism Based PK/PD for Translation

Meindert Danhof, Ph.D.
Leiden University

Integrative Biology Approaches for Target Selection

Debra N. Klatte, Ph.D.
Boehringer-Ingelheim

Integrating Dissolution Testing with Permeability to Predict Product Performance (PPB & FDD)

Session Chairs

Lillian Zhang, Ph.D.
U.S. Food and Drug Administration

Tuesday, November 16 • Program-at-a-Glance

James E. Polli, Ph.D.
University of Maryland

Per Artursson, Ph.D.
University of Uppsala

Using Dissolution and Permeability Modeling to Predict Formulation Performance

Bertil Abrahamsson, Ph.D.
AstraZeneca

Dissolution Specifications: Consideration of Dissolution and Permeation Kinetics in Overall Absorption Kinetics

James E. Polli, Ph.D.
University of Maryland

Simultaneous Assessment of Dissolution and Permeation of Oral Drug

Shinji Yamashita, Ph.D.
Setsunan University

TUESDAY MORNING MINI-SYMPOSIA

9:00 am – 11:00 am

Metabolomics in Pharmaceutical Development (PPDM & CPTR)

Session Chair

Rima Kaddurah, Ph.D.
Duke University

Speakers and Presentation Titles to be Determined

Risk Management Planning: An Essential Component of Pharmacovigilance (RS & SS)

Session Chairs

Carlos Langezaal, Ph.D.
TOPRA

Yusuke Tanigawara, Ph.D.
Keio University

Summary of the Work and Outcome of the ICH E2e Working Group and the Impact on Pharmacovigilance Activities

Yusuke Tanigawara, Ph.D.
Keio University, School of Medicine

FDA Experience with Recently Issued Industry Guidance Documentation on Risks Evaluation and Minimization Systems

Gerald Dalpan, M.D. (Invited)
U.S. Food and Drug Administration

Pharmacovigilance and Risk Management Planning with Principles and Practicalities from a Global Industry Perspective

Nayan Acharya, MBBS, MRCP
Eli Lilly and Co.

Ocular Drug Delivery (PPB & PPDM)

Session Chairs

Arto O. Urtti, Ph.D.
University of Helsinki

Hideyoshi Harashima, Ph.D.
Hokkaido University

Anterior Segment Drug Delivery Systems: Challenges and Solutions

Hitoshi Sasaki, Ph.D.
Nagasaki University

Drug Delivery to Posterior Segments: Barriers, Delivery Systems and Models

Arto O. Urtti, Ph.D.
University of Helsinki

Encapsulated Cell Technology for the Retinal Drug Delivery


Weng Tao, M.D., Ph.D.
Neurotech

EXPOSITION & CAREER CENTER

9:30 am – 6:15 pm

Exposition

AAPS Career Center

Funded by a Grant from  AstraZeneca
life inspiring ideas

HOT TOPICS

12:00 pm – 1:15 pm

Topic #3 to be Determined

Topic #4 to be Determined

AAPS FOCUS GROUP MEMBERSHIP

MEETINGS

12:00 pm – 1:00 pm

CONTRIBUTED PAPERS POSTER SESSION

1:00 pm – 5:00 pm

TUESDAY AFTERNOON PROFESSIONAL DEVELOPMENT SESSIONS

1:00 pm – 3:00 pm

Networking Strategies

Brianna Blaser, Ph.D.
AAAS/Science Careers

TUESDAY AFTERNOON PROFESSIONAL DEVELOPMENT SESSIONS

(continued from page 19)

2:00 pm – 4:00 pm

Transitioning Between Academia and Industry

Megan Driscoll
PharmaLogics

TUESDAY AFTERNOON SYMPOSIA

1:30 pm - 4:00 pm

Biosimilars and Follow-on Biologics: A Global Perspective (BIOTEC & RS)

Session Chairs

Robert G. Bell, Ph.D.
Drug & Biotechnology Development, LLC

Teruhide Yamaguchi, Ph.D.
National Institute of Health Sciences

The U.S. FDA Perspective

Keith Webber, Ph.D. (Invited)
U.S. Food and Drug Administration

The EMEA Perspective

Marie-Christine Bielsky, M.D.
MHRA

The Japanese Perspective

Teruyo Arato, Ph.D.
Pharmaceutical and Medical Devices Agency

The Asian Experience

Junzhi Wang, Ph.D.
State Food and Drug Administration

Pharmaceuticals Without Borders II: The Regulatory and Supply Chain Challenges of Providing Medicines to Emerging Markets (GH)

Session Chairs

Kenneth Norris, Ph.D.
Pfizer Inc.

John F. Carpenter, Ph.D.
University of Colorado

Overcoming the Challenges of Regulatory Filing and Supplying Pharmaceuticals to Emerging Markets

Speaker to be Determined
World Health Organization

CPPs (Certificate of Pharmaceutical Products)

and Associated Challenges for International Registration Submissions

Julie Dennis, Ph.D.
Pfizer Global Research & Development

How Can QbD Submissions be used in Emerg- ing Markets

Adran Sabir, Ph.D.
Dr. Reddy's Laboratories Ltd

Penetrating the Brain (PPDM)

Session Chairs

Margareta Hammarlund-Udenaes, Ph.D.
University of Uppsala

Jean-Michel Scherrmann, Ph.D.
University of Paris Descartes

Drug Discovery Aspects of Brain Penetration: How to Optimize New Drugs

Margareta Hammarlund-Udenaes, Ph.D.
University of Uppsala

Transporter Expression and Anticancer Drug Distribution to Brain Tumors

Quentin Smith, Ph.D.
Texas Tech University Health Sciences Center

Molecular Mechanisms of Transport Systems at the Blood-brain Barrier as a Pathway and Target of Drugs

Sumio Ohtsuki, Ph.D.
Tohoku University

Balance Between Transport and Enzyme Activity in the Blood-brain Barrier Influences Drug Penetration in the Brain

Jean-Michel Scherrmann, Ph.D.
University of Paris Descartes

Single Cell Analyses for Accelerating Drug Discovery and Diagnosis (DDD & APQ)

Session Chair

Tsutomu Masujima, Ph.D.
Hiroshima University

Chemical Cytometry: The Chemical Analysis of Single Cells

Norman Dovichi, Ph.D.
University of Washington

Single Cell Analysis for High-throughput Screening

Renato Zenobi, Ph.D.
ETH Zurich

Introduction of Metal Nanoparticles and Metal Nanorods into Cells for Drug Delivery and Disease Diagnosis

Edward S. Yeung, Ph.D.
Iowa State University

Live Single-cell Mass Spectrometry for Drug Discovery and Diagnosis

Tsutomu Masujima, Ph.D.
Hiroshima University

Novel Drug Delivery Systems: Definition of New Excipients (FDD & PPB)

Session Chairs

Otilia M. Koo, Ph.D.
Bristol-Myers Squibb

Paul Wan Sia Heng, Ph.D.
National University of Singapore

Advances and Examples of New Excipients in Novel Drug Delivery Systems

Otilia M. Koo, Ph.D.
Bristol-Myers Squibb

Characterization Requirements of New Excipients

Thorsten Schmeller, Ph.D.
BASF Corporation

Updates on New Excipients Evaluation Procedure by IPEC

Richard C. Moreton, Ph.D.
Finnbrit Consulting

Regulatory Approval Process for Drug Products Containing New Excipients: Case Studies

Wendy Dulin, Ph.D.
Pfizer Inc.

Standards for Essential Drugs (APQ)

Session Chairs

Anthony J. DeStefano, Ph.D.
United States Pharmacopeia

Raimar Loebenberg, Ph.D.
University of Alberta

The Value of In Vitro Dissolution Testing

Raimar Loebenberg, Ph.D.
University of Alberta

Biowaivers Based on the Biopharmaceutics Drug Classification System

Jennifer Dressman, Ph.D.
Johann Wolfgang Goethe University

Comparison of the Pharmaceutical Quality of Essential Drugs on the South American Market

Nadia A. Chacra, Ph.D.
University of Sao Paulo

The Role of the USP in Providing Needed Standards

Roger L. Williams, M.D.
United States Pharmacopeia

Bridging the Gap between Traditional Medicine and the Western Approach to Natural Products (DDD, GH & APQ)

Session Chairs

Mary A. Murray, Ph.D.
Nutriline Health Institute

Xiaoliang Wang, Ph.D.
Institute of Materia Medica, CAMS

Speakers and Presentations to be Determined

TUESDAY AFTERNOON ROUNDTABLES

2:00 pm - 4:00 pm

Technology Transfer and Process Validation in the Context of QbD (RS & MSE)

Session Chairs

Prabu Nambiar, Ph.D., RAC
Vertex, Inc

Thirunellai G. Venkateshwaran, Ph.D.
Wyeth Research

FDA's New Guidance on Process Validation and FDA's Perspectives on Process Validation Under cGMP Initiative for 21st Century

Rick Friedman, Ph.D. (Invited)
U.S. Food and Drug Administration

Process Validation Under QbD Paradigm: EMEA Perspectives

Evdokia Korakianiti, Ph.D.
European Medicines Agency

Continuous Quality Verification: Alignment of ASTM E-55 Standards with the FDA Process Validation Guidance

Gretchen A. Allison
Pfizer Inc.

Is the Cocktail Approach Useful in the Assessment of Drug-drug Interactions? (PPDM)

Session Chairs

Lillian Zhang, Ph.D.
U.S. Food and Drug Administration

Hiroyuki Kusuhara, Ph.D.
University of Tokyo

Things to Consider in "Cocktail" Approaches

Uwe Fuhr, Ph.D.
University Hospital of Cologne

TUESDAY AFTERNOON ROUNDTABLES

2:00 pm - 4:00 pm (continued from page 21)

Application in Drug Development: An Industry Perspective

Honghui Zhou, Ph.D.
Johnson and Johnson

A Regulatory Perspective on Utilization of Cocktail Approach In Clinical Investigation

FDA Speaker to be Determined

TUESDAY AFTERNOON MINI-SYMPOSIA

2:00 pm - 4:00 pm

Current Status of Oligonucleotide Chemistry and Application (DDD & MCNP)

Session Chairs

Christian Hoe, Ph.D.
University of Sydney

Shigeki Sasaki, Ph.D.
Kyushu University

A New Tool for Site-specific Modification of RNA

Shigeki Sasaki, Ph.D.
Kyushu University

Activating Gene Expression with Small RNAs

David Corey, Ph.D.
University of Texas

Oligonucleotide-based Strategies to Inhibit the Heart-pathogenic Coxsackievirus B3

Jens Kurreck, Ph.D.
University of Stuttgart

Pharmacogenetics: Educating the Doctor, the Pharmacist and the Patient (CPTR, E&C & PPDM)

Session Chairs

Okezie I. Aruoma, Ph.D., D.Sc.
Touro College of Pharmacy

Ross A. McKinnon, Ph.D.
University of South Australia

Hiroshi Suzuki, Ph.D.
University of Tokyo

Drug Interactions, Pharmacogenetics and Pharmacogenomics: Teaching the Pharmacist and the Patient

Okezie I. Aruoma, Ph.D., D.Sc.
Touro College of Pharmacy

Role of Pharmacist in Education of Pharmacogenetics and Pharmacogenomics in Japan

Hiroshi Suzuki, Ph.D.
University of Tokyo

Reforming Pharmaceutical Education to Accelerate the Uptake of Personalized Medicine

Ross A. McKinnon, Ph.D.
University of South Australia

Quality Assurance of Medicines: The Detection of Counterfeits and Adulterants (RS, APQ & SS)

Session Chair

Stephen T. Colgan, Ph.D.
Pfizer Global Research & Development

Counterfeiting from the European Perspective

Aline Franco, Ph.D.
Interpol

Counterfeiting from the AEI Perspective

Roger Bates, Ph.D.
American Enterprises Institution

Strengthening Developing Countries to Detect Counterfeit and Sub-standard Medicines

Patrick Lukulay, Ph.D.
United States Pharmacopeia

AAPS RESEARCH ACHIEVEMENT AWARD

LECTURES

4:00 pm - 5:00 pm

Drug Design & Discovery (DDD) Research Achievement Award Lecture

Funded by a grant from



Formulation Design & Development (FDD) Research Achievement Award Lecture

Funded by a grant from



EXPOSITION COCKTAIL RECEPTION

Funded by Grants from Exhibitors and



4:45 pm - 6:15 pm

Tuesday, November 16 • Program-at-a-Glance

AAPS SECTION MEMBERSHIP MEETINGS AND RECEPTIONS 5:30 pm – 7:15 pm

**Pharmacokinetics, Pharmacodynamics &
Drug Metabolism (PPDM) Section**

OPEN FORUMS 7:00 pm – 9:30 pm


An additional fee is required to attend open forums.

Clinical Pharmacology and Translational Research (CPTTR) Open Forum

Open Source Development of Mechanistic/
Systems Biology Models in Clinical Pharmacology
and Translational Research: Do the Challenges
Outweigh the Potential Benefits?

Regulatory Sciences (RS) Open Forum

Practical Considerations for the 505 (B) (2) Regulatory
Pathway and Patent Protection for Fixed Dose
Combination Products and Other Products



AAPS SUSTAINING SPONSORS

*AAPS Thanks the Following Companies for their Support of the Association
and the*

FIP Pharmaceutical Sciences
2010 WORLD CONGRESS

in association with the
AAPS Annual Meeting
and Exposition

AMGEN[®]

Pioneering science delivers vital medicines™

Catalent

Lilly
Answers That Matter.

AstraZeneca

DPT[®]
A DFB COMPANY

Pfizer

sanofi aventis
Because health matters



**Partnering To Build
The Pharmaceutical
Sciences**



With thirty years of successful drug formulation development

We have earned our spurs

Bend Research has an unrivaled track record of solving the most challenging drug-formulation problems. For three decades, we have been applying our unique combination of scientific know-how and enabling technologies to create value.

Our multidisciplinary expertise allows us to advance clients' compounds from discovery to commercialization by delivering innovative formulation solutions in a timely and cost-effective manner. Our culture of flexibility and creativity makes solving problems with us efficient and fun.

Our broad service offerings – ranging from formulation through cGMP manufacture – allow us to develop the customized answers that our clients need. Working from three state-of-the-art facilities, our 140 highly trained employees partner with clients from idea to implementation.

Bend Research offers a flexible business model tailored to meet your firm's research, financial, and intellectual-property requirements. Our track record shows that we can create significant value even when faced with the most difficult drug-formulation tasks. Based on this track record of success, we know we can help your company.

Bend Research Inc.
Innovators In Pharmaceutical And Health Science Technologies

Where Problems Find Solutions

www.bendres.com

Wednesday, November 17, 2010

6:00 am – 5:00 pm
Speaker Ready Room

7:00 am – 5:30 pm
Registration

7:00 am – 5:00 pm
Press Room

7:00 am – 5:00 pm
Student Lounge

7:00 am – 5:00 pm
International Lounge

WEDNESDAY MORNING SUNRISE

SESSIONS

7:00 am - 8:15 am

Pediatric Drug Development: A Learning Curve for Grown-up Scientists and Regulators (PPDM & FDD)

Session Chairs

Tycho H. Heimbach, Ph.D.
Novartis Pharmaceuticals

Jeffrey Barrett, Ph.D.
Children's Hospital of Philadelphia - University of Pennsylvania

Children are Not Small Adults: Challenges in Pediatric Dose Projection: PK/PD and Clinical Trial Design

Jeffrey Barrett, Ph.D.
Children's Hospital of Philadelphia - University of Pennsylvania

Enzyme Directed Prodrug Activation (DDD & MCNP)

Session Chairs

Majid Moridani, Pharm.D., Ph.D.
Texas Tech University Health Sciences Center

Lawrence L. Fleckenstein, Ph.D.
University of Iowa

The Role of P450 Genetic Variations in Prodrug Design

Majid Moridani, Pharm.D., Ph.D.
Texas Tech University Health Sciences Center

Carboxylesterases: Targets for Drug and Prodrug Efficacy and Pharmacokinetics

Teruko Imai, Ph.D.
Kumamoto University

Improving Oral Absorption of Compounds Using High Energy Forms: Evaluation of Physical Stability (PPB & FDD)

Session Chairs

David T. Vodak, Ph.D.
Bend Research, Inc.

Katsuhide Terada, Ph.D.
Toho University

Physical Stability of Amorphous Formulations: Is it Predictable?

Kohsaku Kawakami, Ph.D.
National Institute for Materials Science, Biomaterials Center

Experimental and Theoretical Methods for Reliable Formulation of Kinetically Stable Solid Amorphous Dispersions

Dwayne T. Friesen, Ph.D.
Bend Research, Inc.

Analytical Techniques

Martyn Davies, Ph.D.
University of Nottingham

Inflammation and Stress Signaling (PCOL & PPDM)

Session Chair

Hiroyuki Arai, Ph.D.
University of Tokyo

Makoto Arita, Ph.D.
University of Tokyo

Speakers and Presentation Titles to be Determined

Nanoparticulate Drug Delivery Systems: Fundamentals (FDD & PPB)

Session Chairs

Himanshu Bhattacharjee, Ph.D.
University of Tennessee

Beom-Jin Lee, Ph.D.
Kangwon National University

Rogério Gaspar, Ph.D.
University of Lisboa

Nanoparticles and Drug Delivery: Basics

Deepak Thassu, Ph.D., M.B.A.
Pharmanova

Presentation Title to be Determined

Beom-Jin Lee, Ph.D.
Kangwon National University

CONTRIBUTED PAPERS POSTER SESSION

8:00 am – 12:00 pm

WEDNESDAY MORNING PROFESSIONAL

DEVELOPMENT SESSIONS

8:00 am – 9:30 am

Fellows Application Process

Satyam M. Upadrashta, Ph.D., RAC
Aradigm Corp.

9:00 am – 11:00 am

Transitioning Between Small and Large Pharma

Megan Driscoll
PharmaLogics

WEDNESDAY MORNING SYMPOSIA

8:30 am - 11:00 am

Wednesday Morning Symposia are supported by a grant from



Implementation of Dried Blood Spot (DBS) Sampling in Regulated Bioanalysis (APQ & PPDM)

Session Chairs

Fabio Garofolo, Ph.D.
Algorithme Pharma, Inc.

Stephen Lowes, Ph.D.
Advion BioServices, Inc.

Introduction to DBS Technique and Comparison Between DBS and Plasma in Incurred Samples

Fabio Garofolo, Ph.D.
Algorithme Pharma, Inc.

Recent Advances and Future Directions in the Use of DBS Samples for the Quantitative Bioanalysis of Drugs

Neil Spooner, Ph.D.
GlaxoSmithKline

Clinical Pharmacokinetic Aspects of DBS: Pros & Cons

Gary T. Emmons, Ph.D.
Sanofi-Aventis

Advantages and Disadvantages of Using DBS Samples in Regulated Bioanalysis: EBF Perspective

Philip Timmerman, M.S.
Johnson and Johnson Pharmaceutical Research & Development

Rational Drug Design and Discovery via Computational Modeling (DDD)

Session Chairs

Chang-Guo Zhan, Ph.D.
University of Kentucky

Akiko Itai, Ph.D.
Institute of Medicinal of Molecular Design, Inc.

Speakers and Presentation Titles to be Determined

Immune Response to Biotechnology Products (BIOTEC & PCOL)

Session Chairs

Eva H. Moller, Ph.D.
University of Copenhagen

Tatsuro Irimura, Ph.D.
University of Tokyo

Dendritic Cells in the Immune Response

Tatsuro Irimura, Ph.D.
University of Tokyo

Immunogenicity of Genetically Modified Foods

Reiko Teshima, Ph.D.
National Institute of Health and Sciences

Predicting Immunogenicity: Assessing the Unwanted Response to Biomolecules

Erwin L. Roggen, Ph.D.
Novozymes

Formulation-related Causes of Immunogenicity

Wim Jiskoot, Ph.D.
Leiden University

Transporter Proteins II: How to Scale In Vitro Data on Human Transporters to Predict In Vivo Outcome (PPDM)

Session Chairs

Sibylle Neuhoff, Ph.D.
Simcyp

Hiroyuki Kusuhara, Ph.D.
University of Tokyo

Involvement and Interaction of Transporters in Intestinal and Pulmonary Absorption of Drugs

Ikumi Tamai, Ph.D.
Kanazawa University

Hepatic Organic Anion Transporters: Role in Drug Disposition and Pharmacogenetics of Acquired Liver Injury

Bruno Stieger, Ph.D.
University of Zurich

Blood-brain Barrier Pharmacoproteomics: Quantitative Transporter Protein Analysis for In Vitro-In Vivo, Interspecies and Diseased State Differences

Tetsuya Terasaki, Ph.D.
Tohoku University

The Role of Transporters During Drug Development: The Perspective from the FDA

Shiew-Mei Huang, Ph.D. (Invited)
U.S. Food and Drug Administration

Imaging Technology for Understanding Process in Pharmaceutical Manufacturing (PPB & MSE)

Session Chair

Etsuo Yonemochi, Ph.D.
Toho University

Insight into Dissolution Processes using Real Time UV Imaging Together with Solid State Analysis with Raman Spectroscopy

Jukka Rantanen, Ph.D.
University of Copenhagen

A Novel Rapid Quantitative Analysis of Drug Migration on Tablets Using Laser Induced Breakdown Spectroscopy

Andre Blain, Ph.D.
Pharma Laser

Terahertz Imaging of Film Coatings: From Research and Development to Real Time Process Control

J Axel Zeitler, Ph.D.
University of Cambridge

Annular Bed Flow Patterns in a Bottom Spray Coating Process and their Influence on Pellet Coat Uniformity

Paul Wan Sia Heng, Ph.D.
National University of Singapore

New Molecular Targets-based Anti-cancer Drugs: From Small Molecules to Antibodies (DDD & BIOTEC)

Session Chairs

Takao Yamori, Ph.D.
Japanese Foundation for Cancer Research

Robert H. Shoemaker, Ph.D.
DPT

Identification of a Novel Pi3k Inhibitor for Cancer Treatment

Takao Yamori, Ph.D.
Japanese Foundation for Cancer Research

Monoclonal Antibody Against Cell Membrane Carbohydrate Antigen as a Possible Cancer Treatment

Tong H. Chang, Ph.D.
GlycoNex Inc.

A New Metastasis Associated Gene, MACC1: From Bench to Bedside

Ulrike Stein, Ph.D.
Max Delbrück Center for Molecular Medicine

Therapeutic Targeting of Alveolar Soft Part Sarcoma

Robert H. Shoemaker, Ph.D.
DPT

Delivery of Poorly Soluble Drugs: Evolving Science and Technology (PPB & FDD)

Session Chairs

Ping Gao, Ph.D.
Abbott Laboratories

Juan M. Irache, Ph.D.
University of Navarra

Lipid Nanocapsules: A Tool for Improving Oral Drug Absorption?

Jean Pierre Benoit, Ph.D.
University of Angers

Overview of Fundamental Aspects of Supersaturation-based Drug Delivery and Drug Product Development

Ping Gao, Ph.D.
Abbott Laboratories

Factors Contributing to the Development of Successful Amorphous Dispersions: Supersaturation and Formulation Stability

Markus Brewster, Ph.D.
Johnson & Johnson

Delivery of Poorly Soluble Drugs: Evaluation of In Vitro and In Vivo Performance

Lawrence Yu, Ph.D. (Invited)
U.S. Food and Drug Administration

Pharmacogenetics: Found in Translation? (CPTR & PPDM)

Session Chairs

Anke-Hilse Maitland-van der Zee, Pharm.D.
Utrecht University

Donna Arnett, Ph.D.
University of Alabama at Birmingham

Stephen Kimmel, M.D., Ph.D.
University of Pennsylvania

Introduction in Pharmacogenetics

Anke-Hilse Maitland-van der Zee, Pharm.D.
Utrecht University

WEDNESDAY MORNING SYMPOSIA

Wednesday Morning Symposia are supported by a grant from



8:30 am – 11:00 am (continued from page 27)

Pharmacogenetics of Adverse Drug Reactions

Ann Daly, Ph.D.
Newcastle University

Pharmacogenetics of Antidepressants

Julia Kirchheiner, Ph.D.
Ulm University

How do we Bring Pharmacogenetics into Practice?

Stephen Kimmel, M.D., Ph.D.
University of Pennsylvania

WEDNESDAY MORNING ROUNDTABLES

9:00 am - 11:00 am

Development and Evaluation of Academic Curriculum and Clinical Clerkship for Modern Pharmaceutical Education (E&C)

Session Chairs

Tetsumi Irie, Ph.D.
Kumamoto University

Henri Manasse, Ph.D.
American Society of Health-system Pharmacists

Issues and Challenges in Contemporary Pharmacy Education in Practice & Science

Jerry L. Baumann, Pharm.D.
University of Illinois at Chicago

Curriculum Development: Content and Policies

Koichiro Ozawa, Ph.D.
Hiroshima University

Experiential Education in Clinical Practice

Steven L. Sheaffer, Pharm.D.
University of the Sciences in Philadelphia

Dissolution Testing: Relevance in a Quality by Design Approach to Drug Release (APQ & FDD)

Session Chairs

Saji K. Thomas, Ph.D.
Par Pharmaceutical

Horst-Dieter Friedel, Ph.D.
Bayer Schering Pharma

Vivian A. Gray
V. A. Gray Consulting, Inc.

Dissolution and QbD: An EMEA Perspective
Speaker to be Determined

Dissolution and Its Relevance in Life Cycle of a Product: An FDA Perspective

Patrick Marroum, Ph.D. (Invited)
U.S. Food and Drug Administration

Dissolution and QbD an Industry Perspective

Andreas Abend, Ph.D.
Merck & Co., Inc.

WEDNESDAY MORNING MINI-SYMPOSIA

9:00 am – 11:00 am

Nanotechnology: Clinical Aspects (CPTR & FDD)

Session Chair

Yasuhiro Matsumura, M.D., Ph.D.
National Cancer Center Hospital East

Speakers and Presentation Titles to be Determined

Nuclear Receptors: Important New Players in Pharmacology (PCOL & DDD)

Session Chairs

Heyo K. Kroemer, Ph.D.
Ernst Moritz Arndt University

Erin Schuetz, Ph.D.
St. Jude Children's Research Hospital

Nuclear Receptors and Transport Proteins: From Physiology to Therapeutic Relevance

Henriette M. Schwabedissen, M.D.
Ernst Moritz Arndt University

Car at the Crossroads of Xenobiotic Metabolism, Diabetes and Fatty Liver Disease

David D. Moore, Ph.D.
Baylor College of Medicine

HNF4: Its Ligand and Drug Prospects

Frances M. Sladek, Ph.D.
University of California, Riverside

The Globalization of Pharmaceutical Regulation (RS)

Session Chair

Carlos Langezaal, Ph.D.
TOPRA

Setting Up the Office of International Programs Within the Japanese PMDA and the PMDA Mechanisms for Sharing Information Between Health Authorities

Toshiyoshi Tominaga, Ph.D.
Pharmaceuticals and Medical Devices Agency

FDA Mechanisms for Sharing Information Between Regulators

Janice Soreth, Ph.D. (Invited)
U.S. Food and Drug Administration

EMA Mechanisms for Sharing Information Between Health Authorities

Hilde Boone
European Medicines Agency

Cutting Edge in Vaccine Delivery (BIOTEC)

Session Chairs

Shinsaku Nakagawa, Ph.D.
Osaka University

Kazuo Maruyama, Ph.D.
Teikyo University

DDS Technology for Dc-based Cancer Immunotherapy

Shinsaku Nakagawa, Ph.D.
Osaka University

Cancer Immunotherapy Utilized Ultrasound Sensitive Liposomes (Bubble Liposomes)

Ryo Suzuki, Ph.D.
Teikyo University

Transcutaneous and Intradermal Vaccination by Means of Microneedles and Nanoparticles

Joke Bouwstra, Ph.D.
Leiden University

Transcutaneous Vaccination System Using a Hydrogel Patch Formulation

Naoki Okada, Ph.D.
Osaka University

AAPS FOCUS GROUP MEMBERSHIP MEETINGS

12:00 pm – 1:00 pm

CONTRIBUTED PAPERS POSTER SESSION

1:00 pm – 5:00 pm

WEDNESDAY AFTERNOON PROFESSIONAL DEVELOPMENT SESSIONS

1:00 pm – 3:00 pm

How to Publish in an AAPS Peer-reviewed Academic Journal

Carolyn Honour
Springer

2:00 pm – 4:00 pm

Strategic Job Search

Megan Driscoll
PharmaLogics

WEDNESDAY AFTERNOON SYMPOSIA

1:30 pm - 4:00 pm

Pharmaceuticals Without Borders III: Ensuring the Integrity and Quality of Medicines Reaching the Patient (GH)

Session Chairs

Sabine Kopp, Ph.D.
World Health Organization

Cynthia K. Brown, Ph.D.
Eli Lilly & Co.

The Challenges of Delivering Quality Medicines to a Global Patient Population

Andreas Seiter, Ph.D.
The World Bank

Ensuring the Quality of Pharmaceutical Ingredients and Finished Products: Scope, Impact and Prevention

Adriaan J. van Zyl, M.Pharm, Ph.D.
World Health Organization

The Impact of Diversion within the Global Supply Chain

Martin G. Fitzgerald, M.S., J.D.
GIRP - European Association of Pharmaceutical Full-line Wholesalers

EXPOSITION & CAREER CENTER

9:30 am – 4:30 pm

Exposition

AAPS Career Center

Funded by a grant from




HOT TOPICS

12:00 pm – 1:15 pm

Topic #5 to be Determined

Topic #6 to be Determined



WEDNESDAY AFTERNOON SYMPOSIA

1:30 pm – 4:00 pm (continued from page 29)

A Case Study: How to Address Drug Quality with Local Resources

Shaohong Jin, Ph.D.
National Institute for the Control of Pharmaceutical and Biological Products

Pharmacogenetics: Translational Aspects (CPTR & PPDM)

Session Chairs

Urs A. Meyer, M.D.
University of Basel

Mary V. Relling, Pharm.D.
St. Jude Children's Research Hospital

The Contribution of Pharmacogenetics to Personalized Medicine

Urs A. Meyer, M.D.
University of Basel

Pharmacogenetic Variation in Smoking and Treatment Response

Rachel F. Tyndale, Ph.D.
University of Toronto

Clinical Pharmacogenomics in Cancer

Mary V. Relling, Pharm.D.
St. Jude Children's Research Hospital

Pharmacogenomics of Drug Hypersensitivity Reactions

Munir Pirmohamed, M.D., Ph.D.
The University of Liverpool

In Vitro Release of Drugs from Non-oral Dosage Forms (PPB, APQ & FDD)

Session Chairs

Todd L. Cecil, Ph.D.
U.S. Pharmacopeia

Chikako Yomota, Ph.D.
National Institute of Health Sciences

Horst-Dieter Friedel, Ph.D.
Bayer Schering Pharma

Review of FIP: Special Dosage Forms Guidance

J. Michael Morris, Ph.D.
Irish Medicines Board

Unique Issues for Inhalation Products

Neal Davies, Ph.D., R.Ph.
Washington State University

New Approaches for Complex Parenteral Products

Diane J. Burgess, Ph.D.
University of Connecticut

Targeted Intracellular Drug Delivery with Liposomes

Kazuo Maruyama, Ph.D.
Teikyo University

Natural Products: Interface Between Science and Practice (DDD & MCNP)

Session Chairs

Carmen Tamayo, M.D.
Foresight Links Corporation

Michiho Ito, Ph.D.
Kyoto University

Health Claims and Botanical Drug Development: From Seed to Patients

Carmen Tamayo, M.D.
Foresight Links Corporation

Field Research on Herbal Medicines and Related Research Works Aiming at their Development and Use in Practice

Michiho Ito, Ph.D.
Kyoto University

Quality, Efficacy and Safety of Herbal Medicines

Silvia Etcheverry, Pharm.D.
Bioxel Laboratory

Quality Control of NPS: An Evidence Based Approach

Paula Brown, M.S.
British Columbia Institute of Technology

Preservatives in Parenteral Products (FDD & BIOTEC)

Session Chair

Qiang Ye, Ph.D.
Otonomy, Inc.

Current Preservative Use in Parenteral Drug Products

Sandeep Nema, Ph.D.
Pfizer Global Biologics Pharmaceutical

Preservative-drug, Preservative-excipient and Preservative-package Interactions

Tony Pidgeon, Ph.D.
Patheon, Inc.

Preservative-free Sterile Products

David S. Baker, Ph.D.
QLT Plug Delivery, Inc.

Regulatory Landscape of Preservatives in Parenteral Drug Products

Elaine Morefield, Ph.D. (Invited)
U.S. Food and Drug Administration

Nanocrystals: Production, Stability and Applications (MSE & PPB)

Session Chairs

Jamshed Anwar, Ph.D.
University of Bradford

Rainer H. Müller, Ph.D.
Free University Berlin

Nanocrystals: Properties, Production Methods and Stability Issues

Rainer H. Müller, Ph.D.
Free University Berlin

Targeting Applications of Nanocrystals in Drug Delivery

Barrett E. Rabinow, Ph.D.
Baxter Healthcare Corporation

Towards Stabilizing Nanocrystals: Calculation of Surface & Interfacial Free Energy

Jamshed Anwar, Ph.D.
University of Bradford

Phase Stability of Inorganic Nanocrystals: Lessons for Organic Nanocrystals

Amanda S. Barnard, Ph.D.
CSIRO Materials Science & Engineering

Prediction of Human Oral Pharmacokinetic Profiles from Preclinical and In Vitro Data (PPDM)

Session Chairs

Zheng Yang, Ph.D.
Bristol-Myers Squibb

Jin-Ding Huang, Ph.D.
National Cheng Kung University

Application of PBPK to the Prediction of Human Concentration - Time Profiles from Preclinical Data: Pfizer Experience

Hannah Jones, Ph.D.
Pfizer Global Research & Development

Prediction of Human Pharmacokinetic Profiles Based on *In Silico* Approaches and Normalization of Animal PK Profiles

Toshihiro Wajima, Ph.D.
Shionogi & Co.

Evaluation of Various Methodologies in Predicting Human Oral Pharmacokinetic Profiles from Preclinical Data: Experience with BMS Compounds

Zheng Yang, Ph.D.
Bristol-Myers Squibb

Pharma Initiative in Human PK Prediction to Shorten the Cycle Time with Improved Efficiency for New Drug Development

Sherry Ku, Ph.D.
Wyeth Pharmaceuticals

siRNA Delivery: Challenges and Opportunities (DDD & BIOTEC)

Session Chairs

Majid Moridani, Pharm.D., Ph.D.
Texas Tech University Health Sciences Center

Hiroaki Okada, Ph.D.
Tokyo University of Pharmacy and Life Sciences

Non-viral and Disease-specific Delivery Systems for siRNA Therapy

Ick Chan Kwon, Ph.D.
Korea Institute of Science and Technology

Transdermal Preparation for Treating Atopic Dermatitis in Mice by siRNA

Hiroaki Okada, Ph.D.
Tokyo University of Pharmacy and Life Sciences

Development of Targeted Nanogels for siRNA Delivery to Tumor Vasculature

Rakesh K. Singh, Ph.D.
University of Nebraska Medical Center

Non-viral Approaches for Gene Drug Discovery and Gene Therapy

Dexi Liu, Ph.D.
University of Pittsburgh

WEDNESDAY AFTERNOON ROUNDTABLES

2:00 pm - 4:00 pm

What Do Industry and Regulators Need from Imaging? (CPTR & RS)

Session Chairs

Narayan P. Cheruvu, Ph.D.
Covidian Ltd

Mary E. Spilker, Ph.D.
Pfizer Global Research & Development

Speakers and Presentation Titles to be Determined

PK: Bottom-up, Top-down or Both? (PPDM)

Session Chairs

Geoff Tucker, Ph.D.
Academic Unit of Clinical Pharmacology

Yuichi Sugiyama, Ph.D.
The University of Tokyo

Presentation Title to be Determined

Nick Holford, M.D., M.S.
University of Auckland

Presentation Title to be Determined

Amin Rostami-Hodjegan, Ph.D., Pharm.D.
University of Sheffield

WEDNESDAY AFTERNOON MINI-SYMPOSIA

2:00 pm - 4:00 pm

Computer-aided Drug Development: A Rational Approach to Improve Speed and Reduce the Cost (PPB & FDD)

Session Chairs

Jean M. Surian, Ph.D.
AstraZeneca

Fumiyoshi Yamashita, Ph.D.
Kyoto University

Persuing the Drug-likeness Concept in Drug Discovery

Tudor Oprea, Ph.D.
University of New Mexico

Monte Carlo Simulations to Predict Drug Physical Properties in Aqueous Solutions

Lennart Lindfors, Ph.D.
AstraZeneca

Data Mining and Visualization Techniques for ADME Screening

Fumiyoshi Yamashita, Ph.D.
Kyoto University

New Synthetic Technology in Drug Development (DDD & MCNP)

Session Chairs

Kiyoshi Tomioka, Ph.D.
Kyoto University

Kai-Xian Chen, Ph.D.
Chinese Academy of Science

Drug Discovery

Paul J. Reider, Ph.D.
Princeton University

Asymmetric Synthesis of Pharmaceuticals

Kiyoshi Tomioka, Ph.D.
Kyoto University

Safety Sciences: Education and Training (SS & E&C)

Session Chairs

Ole J. Bjerrum, Ph.D.
University of Copenhagen

A. Wallace Hayes, Ph.D., D.A.B.T.
Harvard University

New Public Private (EU/EFPIA) Supported Pan European Modular Program for Training of Pharmaceutical Safety Scientists

Ole J. Bjerrum, Ph.D.
University of Copenhagen

Where is the U.S. in its Training Program

A. Wallace Hayes, Ph.D., D.A.B.T.
Harvard University

Industrial and Regulatory Needs for Drug Safety Education and Training in a Global Perspective

Eva M. Muchitsch, D.V.M.
Baxter Innovations GmbH

Pharmaceutical Waste and Environmental Pollution (ES & SS)

Session Chairs

Tetsuji Nishimura, Ph.D.
National Institutes of Health

Bent Halling-Sørensen, Ph.D.
University of Copenhagen

Speakers and Presentation Titles to be Determined

AAPS RESEARCH ACHIEVEMENT AWARD LECTURES

4:00 pm - 5:00 pm

Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM) Research Achievement Award Lectures

Funded by Grants from



AAPS FOCUS GROUP MEMBERSHIP MEETINGS

5:00 pm - 6:00 pm

PSWC CLOSING DINNER

7:00pm-10:00pm

*An additional fee is required for this event.
Court of Two Sisters Pavilion*

as of March 10, 2010

Thank you for your support!

SUSTAINING SPONSORS

AMGEN[®]

Pioneering science delivers vital medicines™

AstraZeneca 

Catalent 

DPT[®]

A DFB COMPANY

Lilly
Answers That Matter.

Pfizer

sanofi aventis

Because health matters

SUPPORTER LEVEL

CAPSUGEL[®]

Quality
People and Products Working Together™

DIAMOND LEVEL

 **EVONIK**
INDUSTRIES

PLATINUM LEVEL


AAIPHARMA[®]


Daiichi-Sankyo


Baxter

FMC


VETTER

 **Cetero**
Research

SILVER LEVEL

 Douwe D. Breimer
Research Foundation

BRONZE LEVEL

 **EURAND** | Pharmaceutical
Technologies

 **gsk** GlaxoSmithKline

ICON
A Symbol of Excellence
Development Solutions

MEDIA SPONSORS

CONTRACT PHARMA

International **DrugDiscovery**

Pharmaceutical Review

BioPharm
INTERNATIONAL
The Science & Business of Biopharmaceuticals

Pharmaceutical
Outsourcing

Pharmaceutical Technology

Drug Delivery

CONTRACT PHARMACEUTICALS PUBLICATIONS
The Pharma Review

Interested In Sponsoring The FIP PSWC 2010/AAPS Annual Meeting & Exposition?

Contact Grace Jones at Sponsors@aaps.org.

Thank you for your support!



biogen idec



CHIRON



Dale E. Wurster, Ph.D.



FMC



Genentech
A Member of the Roche Group



University of
Colorado Denver
School of Pharmacy

Thursday, November 18, 2010

6:00 am – 12:00 pm
Speaker Ready Room

7:00 am – 2:30 pm
Registration

7:00 am – 12:00 pm
Student Lounge

7:00 am – 12:00 pm
International Lounge

8:00 am – 12:00 pm
Press Room

THURSDAY MORNING SUNRISE SESSIONS

7:00 am - 8:15 am

Fractal Pharmacokinetics and Non-linear Dynamics (PPDM)

Session Chairs

Luis M. Pereira, Ph.D.
Harvard Medical School

Panos E. Macheras, Ph.D.
University of Athens

Nonlinear Dynamics in PK/PD Analysis

Robert R. Bies, Pharm.D., Ph.D.
Indiana University

Nonexponential Transit Time Distributions in Pharmacokinetic Systems

Michael Weiss, Ph.D.
Martin Luther University

Pharmaceutical Stability: Science and Regulation (RS, FDD & PPB)

Session Chairs

Prabu Nambiar, Ph.D., RAC
Vertex, Inc.

Latiff Hussain, Ph.D.
U. S. Food and Drug Administration

Pharmaceutical Stability: Science and Regulation

Prabu Nambiar, Ph.D., RAC
Vertex, Inc.

Stability Requirements for Generic Drug Approvals

Latiff Hussain, Ph.D. (Invited)
U.S. Food and Drug Administration

Traditional Medicines in a New Paradigm of Global Health (DDD, MCNP & CPTR)

Session Chairs

Tsutomu Hatano, Ph.D.
Okayama University

Zuguang Ye, Ph.D.
Chinese Academy of Medical Sciences

Effects of Tannins and Related Polyphenols on Antibiotic-resistant Bacteria

Tsutomu Hatano, Ph.D.
Okayama University

Characterization of Natural Ligands for Aryl Hydrocarbon Receptor Using a Reporter Gene Assay

Yoshiaki Amakura, Ph.D.
Matsuyama University

Standardized Evaluation of TCM Drug Safety and its Safe use in China

Zuguang Ye, Ph.D.
Chinese Academy of Medical Sciences

Personalized Medicine: Integrated Technologies (DDD, CPTR, PPDM & PCOL)

Session Chairs

Wolfgang Sadee, Ph.D.
Ohio State University

Hitoshi Sasaki, Ph.D.
Nagasaki University

Large-scale Genotyping and Full Sequencing in Personalized Medicine: How to Search for the Missing Heritability of Complex Diseases and Response to Therapies

Wolfgang Sadee, Ph.D.
Ohio State University

The Changing Nature of Biomarkers: How to Optimize an Individual's Drug Therapy

Hitoshi Sasaki, Ph.D.
Nagasaki University

CONTRIBUTED PAPERS POSTER SESSION

8:00 am – 12:00 pm

THURSDAY MORNING SYMPOSIA

8:30 am - 11:00 am

Predicting Clinical Outcome Events Using Biomarkers for Drug Development (CPTR)

THURSDAY MORNING SYMPOSIA

8:30 am – 11:00 am (continued from page 35)

Session Chairs

Pollen K. Yeung, Ph.D.
Dalhousie University

Lawrence J. Lesko, Ph.D.
U.S. Food and Drug Administration

Bruno Flamion, M.D., Ph.D.
EMA/CHMP Scientific Advice Working Party

Modeling Clinical Outcome and Biomarker Response in Clinical Trials: Applications and Impact on Decision-making in Drug Development

Richard L. Lalonde, Pharm.D.
Pfizer Inc.

Use of Biomarkers in the Early Clinical Development of a Hypnotic with a New Mechanism of Action

Jasper Dingemans, Pharm.D., Ph.D.
Actelion Pharmaceuticals Ltd.

Role of Biomarker-clinical Outcome Relationship in Clinical Drug Development: FDA Experience

Kevin M. Krudys, Ph.D. (Invited)
U.S. Food and Drug Administration

Open Source Biomarkers: Practice and Pitfalls

John A. Wagner, M.D., Ph.D.
Merck & Co., Inc.

Molecular Imaging Technologies for ADME-Tox Studies

(PPDM, FDD & PPB)

Session Chair

Shinji Yamashita, Ph.D.
Setsunan University

New Strategy of Microdosing Study with Molecular Imaging Technology

Yuichi Sugiyama, Ph.D.
The University of Tokyo

Pharmacokinetic Studies with PET

Bengt Langstrom, Ph.D.
Uppsala University

Molecular Imaging of Oral Drug Absorption with PET

Shinji Yamashita, Ph.D.
Setsunan University

PET and Fluorescent Imaging to Study ADME of Tumor Targeting Antibody

Duxin Sun, Ph.D.
University of Michigan

New Molecular Targets for Drug Discovery (PCOL & DDD)

Session Chairs

Gavin Brooks, Ph.D., M.Pharm
University of Reading

James E. Bradner, M.D.
Dana-Farber Cancer Institute/Harvard Medical School

G-Protein Coupled Receptors as Targets for the Treatment of Human Disease

Martin J. Lohse, Ph.D.
University of Wuerzburg

The Notch Signaling Pathway as a Target for Human Disease

James E. Bradner, M.D.
Dana-Farber Cancer Institute/Harvard Medical School

Targeting the Cell Cycle Machinery for the Treatment of Cardiovascular Disease

Gavin Brooks, Ph.D., M.Pharm
University of Reading

Protein Kinases and Phosphatases as Drug Targets

Alexander Levitzki, Ph.D.
The Hebrew University of Jerusalem

Continuous Manufacturing: Benefits and Challenges (MSE)

Session Chairs

Sharmista Chatterjee, Ph.D.
U.S. Food and Drug Administration

Jiahui Hu, Ph.D.
Novartis

Continuous Micro Reactor Technology for Drug Substance Synthesis

Brian Marquardt, Ph.D.
University of Washington

Continuous Manufacturing for Drug Products

James Kraunsoe, Ph.D.
AstraZeneca, UK

Regulatory Perspective on Continuous Manufacturing

Christine Moore, Ph.D. (Invited)
U.S. Food and Drug Administration

Systems Approaches to Adverse Drug Reactions (SS & PPDM)

Session Chair

Nico Vermeulen, Ph.D.
VU University / LACDR

Reactive Intermediates: The Molecular Basis for Human ADRs

Nico Vermeulen, Ph.D.
VU University / LACDR

Cellular Toxicogenomics as a Predictive Tool for Human ADRs

Bob van de Water, Ph.D.
Leiden University

Pharmacogenomics and Human ADRs

Magnus Ingelman-Sundberg, Ph.D.
Karolinska Institute

Systems Pharmacology Approaches to Study Human ADRs

Kevin Park, Ph.D.
The University of Liverpool

New Frontiers in Biologics Development: Understanding and Mitigating Uncommon Protein Degradation Pathways (BIOTEC & PPB)

Session Chairs

Pankaj V. Paranjpe, Ph.D.
Bristol-Myers Squibb

Vikram Sadineni, Ph.D.
Bristol-Myers Squibb

Zhi-Nan Chen, Ph.D.
Chinese Academy of Engineering

Disulfides and their Stability in Peptides and Proteins

Christian Schöneich, Ph.D.
University of Kansas

The Science of Freezing: Control, Excipients, Storage and Freeze-drying (PPB, MSE & FDD)

Session Chairs

Tapan K. Das, Ph.D.
Pfizer Inc.

Hirofumi Takeuchi, Ph.D.
GIFU Pharmaceutical University

Gerhard Winter, Ph.D.
University of Munich

Process of Freezing and Thawing, and Impact of Slow/Fast Freeze-thaw on Phase Properties

Raj Suryanarayanan, Ph.D.
University of Minnesota

Biologics Freezing, Cryoconcentration and Impact on Stability

Angela T. Kantor, Ph.D.
Wyeth

Freeze Thaw and Freeze Drying of Nanoparticles and Vaccine

Erhard W. Hinrichs, Ph.D.
University of Groningen

Molecular Mobility of Freeze-dried Formulation

Sumie Yoshioka, Ph.D.
National Institute of Health and Sciences

Transporter Proteins III: Clinical Relevance and Applications (PPDM & CPTR)

Session Chairs

Ikumi Tamai, Ph.D.
Kanazawa University

Bruno Stieger, Ph.D.
University of Zurich

Involvement and Interaction of Transporters in Intestinal and Pulmonary Absorption of Drugs

Ikumi Tamai, Ph.D.
Kanazawa University

Hepatic Organic Anion Transporters: Role in Drug Disposition and Pharmacogenetics of Acquired Liver Injury

Bruno Stieger, Ph.D.
University of Zurich

Blood-brain Barrier Pharmacoproteomics: Quantitative Transporter Protein Analysis for In Vitro-In Vivo, Interspecies and Diseased State Differences

Tetsuya Terasaki, Ph.D.
Tohoku University

The Role of Transporters During Drug Development: The Perspective from the FDA

Shiew-Mei Huang, Ph.D. (Invited)
U.S. Food and Drug Administration

THURSDAY MORNING MINI-SYMPOSIA

9:00 am - 11:00 am

Similarities and Differences in Global Safety Regulation (SS & RS)

Session Chairs

Prabu Nambiar, Ph.D., RAC
Vertex, Inc.

Eva-Maria Muchitsch, Ph.D.
Baxter Innovations GmbH

Drug Development and Evolution of Current Global Safety/Pharmacovigilance Regulations

Jack Weet, Ph.D.
Vertex, Inc.

THURSDAY MORNING MINI-SYMPOSIA

9:00 am – 11:00 am (continued from page 37)

Challenges and Practical considerations of Implementing a Global Safety/Pharmacovigilance Program: US Perspectives
Speaker to be Determined

Challenges and Practical Considerations of Implementing a Global Safety/Pharmacovigilance Program: EU Perspectives
Eva-Maria Muchitsch, Ph.D.
Baxter Innovations GmbH

Genotoxic and Carcinogenic Impurities: Control and Regulation (APQ & RS)

Session Chairs

Arya P. Jayatilaka, Ph.D.
Pfizer Inc.

Jan Zorgdrager, Ph.D.
Solvay Pharmaceuticals B.V.

A Rationale for Determining, Testing and Controlling Specific Impurities in Pharmaceuticals that Possess Potential for Genotoxicity
Gopi Vudathala, Ph.D.
Sanofi-Aventis

Advances in Analysis of Genotoxic Impurities in API

Arya P. Jayatilaka, Ph.D.
Pfizer Inc.

Quality of Manufactured Medicines – Genotoxic Impurities: Current Perspectives
Peter Kasper, Ph.D.
Federal Institute for Drugs and Medical Devices

Individualizing (Small Molecule) Drugs: From Subtype Specificity to Multi-target Design and Metabolic Network Strategies (DDD & PCOL)

Session Chair

Christian R. Noe, D.Sc., M. Pharm.
University of Vienna

From Genome to Drugs: Assessing Kinase Inhibitor Selectivity and Implications for Drug Discovery
Patrick P. Zarrinkar, Ph.D.
Ambit Biosciences

Design of Multi-target Drugs
Klaus P. Bøgesø, D.Sc.
Lundbeck

Differential Network-based Strategies: Counting on Data

Hans V. Westerhoff, Ph.D.
University Manchester

Lipid-based Drug Delivery Systems (FDD, PPB & MSE)

Session Chairs

Dawn D. Downey, Ph.D.
Patheon, Inc.

Yunxia (Vivian) Bi, Ph.D.
AstraZeneca

Formulation Development Using Lipid Excipients

Chris Porter, Ph.D.
Monash University

Physical Characterization of Semi-solid Lipidic Formulations

Duncan Q.M. Craig
University of East Anglia

The Science and Art of Manufacturing Soft and Hard Shell Liquid-filled Capsules

David Fulper, Ph.D.
Catalent Pharma Solutions, Inc.

Excipients for Protein Drugs Revisited (BIOTEC & APQ)

Session Chairs

Hanns-Christian Mahler, Ph.D.
F. Hoffmann-La Roche Ltd.

Mary Cromwell, Ph.D.
Genentech, Inc.

Excipients for Protein Formulation Revisited

Hanns-Christian Mahler, Ph.D.
F. Hoffmann-La Roche Ltd.

Crystallization of Excipients

Tim Kamerzell, Ph.D.
Genentech, Inc.

The Use and Fate of Polysorbates in Protein Formulations

Kishore Ravuri, Ph.D.
F. Hoffmann-La Roche Ltd.

BCS and BDDCS Based Strategies for Oral Drug Development (FDD & PPDM)

Session Chairs

Leslie Z. Benet, Ph.D.
University of California

Hiroaki Yuasa, Ph.D.
Nagoya City University

Presentation Title to be Determined

Leslie Z. Benet, Ph.D.
University of California

**Risk Factors in Human Bioequivalence
of Oral Dosage**

Shinji Sakuma, Ph.D.
Setsunan University

**Pharmaceutical Challenges to Alzheimer's Disease
(DDD & MCNP)**

Session Chairs

Takeshi Iwatsubo, Ph.D.
University of Tokyo

Peter Seubert, Ph.D.
Elan Corporation

Alzheimer Drug Mechanisms

Taisuke Tomita, Ph.D.
University of Tokyo

Presentation Title to be Determined

Peter Seubert, Ph.D.
Elan Corporation

Presentation Title to be Determined

Douglas Galasko, Ph.D.
University of California

Presentation Title to be Determined

Bart De Strooper, Ph.D.
Katholik University of Leuven

**FIP PSWC 2010/AAPS ANNUAL MEETING &
EXPOSITION ADJOURNMENT**
12:00 pm



Thursday, November 18, 2010

POST-CONGRESS EVENTS

OPEN FORUMS

1:00 pm - 5:00 pm

An additional fee is required to attend open forums.

Formulation Design & Development (FDD) Open Forum

Formulation Strategies for Poorly Soluble Drugs

Including Selected Highlights from the AAPS 2010
Arden Conference

1:30 pm - 5:00 pm

Analysis and Pharmaceutical Quality (APQ) Open Forum

Global Harmonization of Modern Bioanalytical
Regulatory Practices

APQ Open Forum is supported by grants from



Advion



Manufacturing Science & Engineering (MSE) Open Forum

Particles in Biopharmaceutical Parenteral Products

MSE Open Forum is supported by a grant from



Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM) Open Forum


Ethnic Sensitivity in PK/PD: Leveraging Clinical
Development in Emerging Countries — Using
Knowledge of Ethnic Differences to Facilitate
Drug Development

Physical Pharmacy & Biopharmaceutics (PPB) Open Forum

The BCS, BDDCS and Regulatory Guidances

Regulatory Sciences (RS) Open Forum

Establishing Clinically Relevant Dissolution
Specifications in the Quality-by-Design World:
Practical Implications and Regulatory Challenges



Travelship Information

AAPS and FIP are pleased to provide student travelship to the FIP PSWC 2010/AAPS Annual Meeting & Exposition in New Orleans, Louisiana, November 14-18, 2010. Below are the criteria for travelship acceptance. Applications are due on May 12, 2010.

Awardees will be notified of acceptance by July 15, 2010.

Travelship Criteria:

1. Must have a paper submitted and accepted to the PSWC/Annual Meeting & Exposition or the Student and Postdoctoral Fellow Meeting.
2. International awardees will receive the funding in person at the meeting
3. Must be traveling more than 300 miles from New Orleans
4. Applicants must be the presenting author or first author on the paper.
5. Applicants must be a full time student or employed as a post-doctoral fellow. Verification will be required by an Advisor, Department Chair or Dean of the College or School.
6. Applicants can only receive one travelship. If applicant is an award winner, he/she is not eligible for a travelship.

**FIP PSWC 2010/AAPS Annual Meeting &
Exposition Travelship Application**
www.pswc2010.org/travelships

AAPS *eLearning*

It's Education Anytime

WEBCASTS

VIDEOS

PODCASTS

CD-ROMs



For complete details, visit AAPS eLearning on the Web

www.aapspharmaceutica.com/DL08

Short Course Application Form

For Graduate Students and Postdoctoral Fellows Only

The first five applicants per short course will be selected to purchase short course registration for the reduced rate of \$50. Reduced fees are available on a space-available basis. Please print or type. Incomplete forms will not be considered. Reduced fees are not applicable after October 8, 2010.

Please print or type. Incomplete forms will not be considered.

First Name _____

Last (Family) Name _____

AAPS Member ID (required) _____

Institution _____

Address _____

City _____

State/Province _____

Postal Code _____

Country _____

Day Phone _____

Evening Phone _____

Fax _____

Email _____

Are you a member of an AAPS Student Chapter?

Yes No

If so, which one? _____

Payment Method

AAPS does not accept government training forms nor purchase orders. Federal Tax ID #521444968

Check # _____ Payable to: AAPS-2010PSWC/AM
 (U.S. dollars drawn on a U.S. bank)

Charge
 Visa MasterCard American Express Discover

Card Number _____

Exp. Date _____

Card Holder's Name _____

Authorized Signature _____

Amount to Charge _____

Short Course Selections

My top three choices are (rank in order with #1 as your first choice):

Sunday, November 14, 2010 • 8:30 am – 4:00 pm

_____ **SC #1: Stability Testing in Pharmaceutical Development**

_____ **SC #2: Mechanistic PK/PD Modeling**

_____ **SC #3: ICH Guidelines Q8, Q9, Q10 and Q11: How Do They All Fit Together?**

_____ **SC #4: Nanotechnology from A-Z: Achievement in Drug Delivery and Tissue Engineering**

_____ **SC #5: Helping the Medicine Go Down - Pediatric Medicines: Formulation, Manufacturing and Compliance Challenges**

_____ **SC #6: Developments in Technologies for Process Related Impurities Detection and Identification for Biologics**

Up to five applicants will be selected for each Short Course on a first-come, first-served basis.

- I am also registered for the FIP PSWC 2010/AAPS Annual Meeting and Exposition.
- I want to purchase Continuing Education Credits for the Short Course.

A reduced registration fee of \$50 will be requested upon notification of acceptance. If you also request Continuing Education Credits, an additional \$50 fee will apply. Applications are not transferable.

The signature of your Dean or Department Chair is required to certify your full-time status to be eligible for this fee.

Signature _____

Date _____

- If I am not accepted for a reduced, charge me for the full rate for the Short Course selected.

Mail or fax this form to:

2010 Short Course Application Form
 AAPS
 Attn: Kate McHugh
 2107 Wilson Blvd., Suite 700
 Arlington, VA 22201-3042

Fax: (703) 243-5582

Questions? Phone: (703) 248-4793
Email: registration@aaps.org

Deadline: October 8, 2010

Register!



Short Courses for the Pharmaceutical Industry May 2010 • Madison, WI

Monday	Tuesday	Wednesday	Thursday	Friday
3	4	5	6	7
Practical Toxicology in Drug Development				
Preformulation and Stabilization of Pharmaceuticals				
Principles of Solid Dosage Forms				
10	11	12	13	14
Nucleic Acid Therapeutics				
Introduction to the Regulatory Process for Drug Development				
An Introduction to Drug Metabolism and Transporters				
17	18	19	20	21
Applied Pharmacology to Drug Action				
Pharmacokinetics, Bioavailability and Bioequivalence				

Practical Toxicology in Drug Development

The course will cover the regulatory, scientific, and strategy of employing non-clinical toxicology methods and provide a basic understanding of the value and limitations of non-clinical safety evaluations.

Preformulation and Stabilization of Pharmaceuticals

The purpose of this course is to provide the learner with an understanding of the underlying scientific principles governing the development of solid dosage forms.

Principles of Solid Dosage Forms

The objective of this short course is to provide the formulation and analytical scientist with an understanding of preformulation science, physical and chemical characterization, and stability of solid- and liquid-dosage forms.

Nucleic Acid Therapeutics

The intent of this short course is to provide an introduction to various classes of nucleic acid therapeutics, including gene therapy, antisense oligonucleotides, microRNA, and siRNA.

Intro to the Regulatory Process for Drug Development

Participants will find this program to be an excellent up-to-date resource for understanding the regulations related to the development and manufacture of pharmaceutical products.

An Introduction to Drug Metabolism and Transporters

The purpose of this course is to provide the learner with a basic understanding of drug metabolism and its role in drug discovery and development.

Applied Pharmacology to Drug Action

The purpose of this course is to provide the learner with a basic understanding of pharmacology: the effects of drugs on living systems.

Pharmacokinetics, Bioavailability and Bioequivalence

The purpose of this course is to provide the learner with a basic understanding of pharmacokinetics, bioavailability and bioequivalence.

For complete program information or to register online visit our website:
www.pharmacy.wisc.edu/esp/ShortCourses

Join our LinkedIn group: University of Wisconsin Extension Services in Pharmacy Industrial Professional Development

Two great reasons to use The University of Iowa Pharmaceuticals for your next Sterile Product

Since the merger of Pharmaceutical Service and the Center for Advanced Drug Development to form The University of Iowa Pharmaceuticals (UIP), we have made a host of improvements in our Sterile Products operation.

- All of our Clean Rooms are now equipped with automatic vial fillers.
- A new automatic vial washer has been installed in our component preparation area.
- Our lyophilization cycle development capabilities have been significantly enhanced with the purchase of a new integrated differential thermal analyzer, integrated freeze-drying microscope, and development scale lyophilizer.

In addition to sterile product clinical and small scale contract manufacturing services, we continue to offer a full line of contract manufacturing and analytical testing services to support both clinical and small scale commercial products.

The University of Iowa Pharmaceuticals has successfully passed a pre-approval inspection (PAI) for an aseptically filled sterile drug product.

- This accomplishment validates the significant upgrades UIP has made in its sterile products manufacturing area.
- This successful PAI represents the second approval this year for UIP to provide manufacturing and/or testing services to clients in support of commercial products.
- UIP is uniquely positioned to provide contract manufacturing services for low volume parenteral products from inception through commercial launch and beyond.

UIP is offering FREE lyophilization cycle development.*

*Through credit on subsequent batches produced at UIP. Offer subject to a limited time.

For more information visit our website
www.pharmacy.uiowa.edu/uiip

Call: Mickey L. Wells, Ph.D., at 319-335-8674, email: mickey-wells@uiowa.edu

First Name _____ Middle Initial _____
 Last (Family) Name _____ Nickname for Badge _____
 Job Title _____
 Organization _____
 Address _____
 City _____ State/Province _____ Postal Code _____
 Country _____ Phone _____
 Fax _____ Mobile _____
 Email _____
 Emergency Contact Name _____ Phone _____

- The information above has changed.
- I require special services in accordance with the Americans with Disabilities Act.
- Check this box if you do not wish to be included in promotional mailings or faxes from AAPS exhibitors sent prior to the FIP PSWC 2010/AAPS Annual Meeting & Exposition.

Instructions

- Type or print all information.
- **Credit card payments** are available **online only** at www.pswc2010.org
- Payment must accompany your form for registration to be processed.
- Keep a copy of your completed registration form for your records.
- Group and combo registration are available **online only** at www.pswc2010.org
- All information must be completed in full to receive a badge.
- Please fax completed forms to 301-694-5124
- Please mail forms with payment to: FIP PSWC 2010/Annual Meeting PO Box 590 Frederick, MD 21705

AAPS Cancellation Policy

FIP Pharmaceutical Sciences World Congress 2010 in association with the AAPS Annual Meeting & Exposition

All requests for refunds must be submitted in writing and emailed to registration@aaps.org or faxed to (703) 243-5582. Registration refunds will be issued for all requests received by October 15, 2010, less an administrative fee (\$100 for members and non-members/\$30 for student registrants). Refunds will not be issued for requests made after October 15, 2010. Registration substitutions from the same company may be submitted in writing at any time without penalty. If the membership status of the substitute differs from that of the original registrant, a refund or additional charge may apply.

Combination Registration available online only. 10% discount for short course and Full Congress.

Register for the FIP PSWC 2010/ AAPS Annual Meeting and Exposition and a Short Course and receive a 10% discount. Combo registration available ONLINE ONLY at www.pswc2010.org.

Business Information

Primary Job Function (Check One)

- A Academic
- B Consultant
- C Corporate Management
- D Engineer
- E Marketing/Sales
- F Media
- G Production/Planning
- H Purchasing
- I QA/QC
- J R&D
- K Regulatory Sciences
- L Other

Primary Business/Industry (Check One)

- A Academia
- B Analytical Testing Lab
- C Association
- D Biotechnology
- E Contract/Clinical Research
- F Cosmetics
- G Foods
- H Government
- I Manufacturing
- J Materials Manufacturing
- K Medical Devices/Diagnostics
- L Publications
- M Other

Purchasing Authority

- A Authorize
- B Purchase
- C Recommend
- D Specify
- E No Purchasing Authority

Area of Interest (Check All That Apply)

- A Analytical Services
- B Chemicals
- C Chromatography
- D Contract/Clinical Services
- E Dissolution Test Equipment
- F Drug Delivery Systems

- G Excipients
- H Ingredients
- I Packaging
- J Pumps
- K Raw Materials
- L Software
- M Spectroscopy
- N Tablet Presses
- O Test Equipment
- P Other

Please check Registration Type and circle the dollar amount.

Registration

	Early Registration Received on or before September 10, 2010	On-Site Registration Received on September 11, 2010 – on-site
Full Congress*	\$850	\$1,150
Government*	\$620	\$620
Student (PSWC Only)*	\$175	\$210
Student (PSWC + Student Congress)*	\$300	\$350
Will you be attending Magazine Street function? <input type="radio"/> YES <input type="radio"/> NO		
Shuttle to Magazine Street — www.magazinestreet.com	\$5	\$5
Are you a member of an AAPS Student Chapter? <input type="radio"/> YES <input type="radio"/> NO		
One Day Full Congress — Circle One: M T W R	\$250	\$350
One Day Student — Circle One: M T W R	\$65	\$90
Spouse/Guest	\$50	\$60

*Every current active AAPS Member will have their membership term extended for an additional twelve months; membership dues are included in the registration rate, so no need pay your membership renewal dues separately.

Please fax completed forms to 301-694-5124

First Name _____ Last Name _____

Please check Registration Type and circle the dollar amount.

Early Registration

On-Site Registration

Received on or before
September 10, 2010

Received on September 11, 2010 –
on-site

Special Events (an additional Fee is required to attend these sessions)

Short Course	\$790	\$885
Open Forum — Circle One: APQ FDD MSE PPB PPDM RS(2)	\$75	\$100
Open Forum with Dinner — Circle One: CPTR RS(1)	\$175	\$200

Short Course Registration (Additional fee required) — Sunday, November 14, 2010

If registering for a Short Course, check the course in which you wish to enroll and circle the appropriate fee below. Course registration is limited and accepted on a first-come, first-served basis.

- SC #1 – Stability Testing in Pharmaceutical Development
- SC #2 – Mechanistic PK/PD Modeling
- SC #3 – ICH Guidelines Q8, Q9, Q10, Q11: How Do They All Fit Together?
- SC #4 – Nanotechnology from A to Z – Achievement in Drug Discovery and Tissue Engineering
- SC #5 – Helping the Medicine Go Down – Pediatric Medicines: Formulation, Manufacturing and Compliance Challenges
- SC #6 – Developments in Technologies for Process Related Impurities Detection and Identification for Biologics

Open Forum Information

CPTR Open Forum (with Dinner) ~ Tuesday, November 16, 2010 7:00pm – 9:30pm
Open Source Development of Mechanistic/Systems Biology Models in Clinical Pharmacology and Translational Research: Do the Challenges Outweigh the Potential Benefits

PPB Open Forum ~ Thursday, November 18, 2010 1:30pm – 5:00pm
The BCS, BDDCS and Regulatory Guidances

FDD Open Forum ~ Thursday, November 18, 2010 1:00pm – 5:00pm
Formulation Strategies for Poorly Soluble Drugs

RS Open Forum (1) ~ Tuesday, November 16, 2010 7:00pm - 9:30pm
Practical Considerations for the 505 (B) (2) Regulatory Pathway and Patent Protection for Fixed Dose Combination Products and Other Products

MSE Open Forum ~ Thursday, November 18, 2010 1:30pm – 5:00pm
Particles in Biopharmaceutical Parenteral Products

RS Open Forum (2) ~ Thursday, November 18, 2010 1:30pm – 5:00pm
Establishing Clinically Relevant Dissolution Specifications in the Quality-by-Design World: Practical Implications and Regulatory Challenges

PPDM Open Forum ~ Thursday, November 18, 2010 1:30pm – 5:00pm
Ethnic Sensitivity in PK/PD: Leveraging Clinical Development in Emerging Countries – Using Knowledge of Ethnic Differences to Facilitate Drug Development

Workshop 1: AAPS Workshop on Contemporary Challenges and Advances Impacting the Development of Veterinary Pharmaceuticals

Two Day Workshop: Saturday, November 13, 2010 8:30am – 5:00pm and Sunday, November 14, 2010 8:30am – 4:00pm

Workshop	\$1,325	\$1,490
Government	\$450	\$525
Student	\$70	\$80

Workshop 2: AAPS Workshop on Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource and Complex Drug Products

Two Day Workshop: Saturday, November 13, 2010 8:30am – 5:00pm and Sunday, November 14, 2010 8:30am – 4:00pm

Workshop	\$1,325	\$1,490
Government	\$450	\$525
Student	\$70	\$80

Workshop 3: USP Workshop on the Pharmacopeia's Role in Improving Global Health

Two Day Workshop: Saturday, November 13, 2010 8:30am – 5:00pm and Sunday, November 14, 2010 8:30am – 4:00pm

AAPS Member	\$850	\$850
Non Member	\$975	\$975

Workshop 4: ACCP Workshop on 6th International Symposium on Microdialysis ion Drug Research and Development 2010

Two Day Workshop: Saturday, November 13, 2010 8:30am – 5:00pm and Sunday, November 14, 2010 8:30am – 4:00pm

ACCP and AAPS Member Rate	\$825	\$825
Nonmember rate	\$975	\$975
Student/Trainee Member Rate	\$275	\$275
Student/Trainee Nonmember Rate	\$315	\$315

Workshop 5: CRS Workshop on Using Population Pharmacokinetics to Support the Development of Clinically Relevant Specifications for Extended Release Formulations

One Day Workshop: Saturday, November 13, 2010 8:30am – 5:00pm

	\$995	\$1,095
--	-------	---------

Additional Fees

CE Short Course	\$50	\$50
CE Annual Meeting	\$50	\$50
Closing Dinner	\$125	\$125

Located at the *Pavilion of the Two Sisters*: <http://neworleanscitypark.com/pavilion.html>

Tipitina's Music Club Entry Fee:

Please register On-Site at our Tours Desk

Saturday, November 13, 2010 (Music Acts TBA in September)

Shuttle Bus to Magazine Street and Tipitina's Music Club	\$5	\$5
--	-----	-----

Payment Method —

Check or Wire Transfer ONLY

Credit Card Payment Available Online Only at

www.pswc2010.org.

AAPS does not accept purchase orders or government training forms. Federal Tax ID #521444968

Check # _____, Payable to AAPS-2010PSWC/AM (U.S. dollars drawn on a U.S. bank)

Signature _____ Date _____

Total Fees

FIP PSWC 2010/AAPS Annual Meeting & Exposition \$

Special Events

Vet Pharm Workshop	\$
Harmonization Workshop	\$
USP Workshop	\$
ACCP Workshop	\$
CRS Workshop	\$
Short Course	\$
Open Forum(s)	\$
Additional Fees	\$

TOTAL \$

We know why it pays to be correctly formulated



At SOLIQS, we approach the pharmaceutical formulation challenge a little differently than others. We understand that as a formulator or manager responsible for drug development at your company, bioavailability may be a primary focus for your increasing number of poorly soluble candidates and compounds. But we also know that getting the right formulation early on can have a major impact on the development of a product and its future success. From optimizing release, to reducing PK variability, to increasing tolerability and minimizing side-effects, to improving stability and scalability, the

right choices will help to safeguard your products against the challenges of the commercialization process.

We have a broad and flexible portfolio of proven drug delivery solutions that can help you make these choices, including SOLIQS Meltrex[®], our proven melt extrusion technology.

To find out more, visit www.soligs.com
or call us on +1 877 765 4771 (US)
or +49 621 589 2554 (Worldwide).

November 14 – 18, 2010

Ernest N. Morial Convention Center
New Orleans, Louisiana, USA

Program at a Glance



Contract Product Development & cGMP Manufacturing of Pharmaceutical Aerosols

Exemplar Laboratories

Product Development Services

- Formulation development
- Dosage form development
- Analytical chemistry
- Bioanalytical chemistry
- Stability programs
- In vitro BA/BE testing
- Process development
- Preclinical supplies

Exemplar Pharmaceuticals cGMP Manufacturing Services

- State-of-the-art cGMP/GLP facility
- Class 100,000 filling suites for pMDIs, DPIs, nasal and buccal sprays
- Process development and scale up
- Pilot scale manufacturing
- Preclinical, toxicology and clinical supplies
- Dedicated space, staff & equipment available
- Process validation

- Supply chain management
- Labeling and packaging services
- Warehousing


e X e m p l a r
Aerosol Expertise